►
From YouTube: Community Vaccine Advisory Committee Meeting #11
Description
No description was provided for this meeting.
If this is YOUR meeting, an easy way to fix this is to add a description to your video, wherever mtngs.io found it (probably YouTube).
A
I
have
noon
high
noon,
so
I
hope
everybody
brought
their
lunch
and
we're
going
to
start
the
meeting.
Dr
burke
harris
and
dr
pond.
It's
all
yours.
B
Thank
you
so
much
bobby,
and
I
want
to
welcome
everyone
to
another
meeting
of
the
community
vaccine
advisory
committee.
As
you
all
know,
I'm
dr
nadine
burke
harris
california,
surgeon,
general
and
co-chair
of
this
committee.
First,
I
want
to
say
thank
you
to
everyone
for
accommodating
a
last-minute
change
to
the
the
timing
of
the
meeting.
B
We
certainly
apologize
and
we're
grateful
for
your
flexibility
and
for
the
fact
that
so
many
committee
members
were
able
to
make
this
new
time
on
friday
afternoon,
so
very,
very
grateful
and-
and
I
I'll
go
ahead
and
turn
it
over
to
bobby
just
to
review
our
meeting
processes,
and
then
we
can
just
dive
right
in
considering
today
we
have
a
two-hour
meeting
instead
of
a
a
three-hour
meeting
like
we
have
in
the
past,
go
ahead
bobby.
A
A
I
think
everyone's
very
familiar
with
the
fact
that
we
love
for
you
to
keep
your
cameras
on
so
that
we
can
see
you
and
sort
of
pretend
that
we're
in
person
together,
don't
forget
to
use
the
hand
raise
icon,
which
I
think
everyone
is
very
familiar
with
by
now.
We
welcome
our
two
asl
interpreters,
mona
and
judith,
as
well
as
we
have
closed
captioning
as
well
for
our
members
and
for
the
public.
A
The
public
is
in
a
listen
only
mode
in
three
modes:
a
public
telephone
line
in
english,
one
in
spanish
and
also
on
our
youtube,
live
stream
watching
the
proceedings,
if
any
of
the
cvac
members
have
any
technical
difficulties.
If
you
can
just
put
your
technical
question
in
the
chat
we'll
see,
if
we
can
help,
you
find
your
way
to
happiness
with
your
technology
on
this
call.
So
thank
you
very
much
for
that,
dr
burke
harris.
Would
you
like
me
to
go
on
and
review
the
public
comment.
A
Great,
so
we've
received
quite
a
bit
of
public
comment
from
the
last
meeting,
just
as
a
reminder
for
the
members
as
well
as
for
the
public.
We
close
down
the
public
comments,
starting
at
ending
at
five
o'clock
on
the
monday
before
the
wednesday
meeting,
and
because
we
didn't
know
that
we
weren't
having
the
wednesday
meeting
this
week,
we
did
close
it
down
on
that
schedule.
Any
other
public
comment
that's
received
after
that
time
will
be
included
in
the
next
round
of
public
comment.
A
This
just
gave
our
members
more
time
to
read
and
think
about
the
public
comment
that
was
submitted.
We
received
59
pages
of
public
comment,
including
links
to
an
additional
16
pages,
216
individuals
and
organizations
provided
very
thoughtful
and,
in
some
cases,
very
moving
and
passionate
comments.
I
hope
everyone
had
a
chance
to
read
them.
Let
me
summarize
them
quickly
for
you.
A
Three
people
ask
that
we
simplify
the
whole
vaccination
system,
announcing
where
people
can
get
vaccines,
making
public
announcements
and
making
it
much
more
easy
to
access
vaccine
appointments
and
schedules.
A
12
individuals
representing
flight
attendants
requested
that
the
flight
attendant
association
be
allowed
to
join
as
a
member
of
the
community
vaccine
advisory
committee
to
represent
the
transportation
industry,
six
organizations
ask
that
we
use
existing
local
child
care
collaboratives
to
reach
and
vaccinate
child
care
workers
throughout
the
state.
With
the
10
percent
set
aside
for
education
and
child
care
sectors,
one
person
urged
us
to
use
an
age-based
approach
for
all
vaccinations.
A
Another
individual
wrote
asking
us
not
to
use
an
age-based
approach
for
vaccinations
and
one
organization
wrote
and
asked
us
to
use
zip
codes
with
the
highest
incidence
of
coveted
disease
as
the
only
way
to
target
a
vaccination.
Prioritization
six
individuals
with
high
risk
conditions,
disabilities
and
people
on
ihss
acknowledge
that
they
cannot
wait
until
march
15th
to
get
their
vaccinations
and
they'd
like
to
get
them
sooner.
A
Another
individual
asked
that
california
used
the
same
list
of
underlying
medical
conditions
and
disabilities
as
other
states.
Another
individual
asked
that
we
publicize
what
kind
of
verification
or
documentation
individuals
with
high-risk
medical
conditions
and
disabilities
need
to
produce
so
that
they
can
get
their
vaccines.
A
We
had
a
number
of
people
asking
that
the
following
underlying
medical
conditions
and
disabilities
be
added
to
the
list
of
those
groups
that
will
be
able
to
receive
their
vaccines
starting
march
15th,
that
included
rare
lung
disease.
Pneumonia
12
people
advocating
for
cystic
fibrosis,
two
advocating
for
all
types
of
cancer
allergies
to
immune.
A
A
We
had
78
78
organizations
writing
to
ask
us
to
prioritize
higher
people
and
organ
people
experiencing
homelessness
and
organizations
serving
them.
We
had
64
organizations
and
individuals
asking
us
to
prioritize
people
living
in
congregate,
settings,
especially
prisons,
county
jails
and
immigrant
detention
facilities.
A
We
had
15
letters
from
hardware
store
and
home
improvement,
store,
employees,
automotive
retailers
and
their
employees,
cosmetologists,
hair,
stylist,
personal
services
providers,
letter
carriers,
workers
in
banks,
construction,
veterinarians
and
their
staff,
and
that
summarizes
the
public
comment
that
was
received
that
I
know
all
the
members
of
cvac
have
reviewed
in
detail.
Thank
you.
B
Thank
you
so
much
for
that
summary
of
our
public
comments
and
now,
as
we
dive
into
the
the
meeting,
I'd
like
to
start
with
a
quick
reflection
on
how
far
we've
come
through
this
process.
B
I
know
that
last
week
we
certainly
reached
a
a
very
sad
milestone
as
we
reached
500
000
deaths
from
covid
in
the
united
states
and
50
000
here
in
california,
and
I
just
want
to
reflect
because
I
feel
like
so
many
people
that
that
I
know
that
I
have
come
into
contact
with
ever
I've
just
been
hearing
over
and
over
again
that
that
people
have
been
feeling
you
know
so
tired,
so
so
exhausted
and
just
kind
of
feeling
like
we
were
in
a
really
challenging
place
and
as
we
look
ahead
and
see
where,
where
how
far
we've
come
and
where
we
are
right
now,
I
think
that
when,
when
we
look
at
the
month
of
march,
we
have
seen
a
couple
of
things
that
are
also
show
real,
exciting
signs
of
promise
and
progress.
B
So
of
course
we
had
the
fda
emergency
youth
authorization
for
another
vaccine,
the
johnson
johnson
vaccine.
That
is
a
one-shot
vaccine
which
feels
really
exciting,
and
we
heard
the
announcement
from
president
biden
that
he
supported
a
partnership
between
merck
and
johnson
and
johnson
to
produce
even
more
of
the
vaccine
and
that
he
anticipates
that
we
will
have
enough
supply
for
every
adult
in
the
united
states
by
the
end
of
may.
B
B
And
so
we
see
that
in
california,
we
have
looked
at
the
data
about
equity
in
our
allocation,
and
we
have
really
made
an
intentional
effort.
As
soon
as
we
have,
you
know,
moved
through
doing
the
important
work
of
vaccinating
our
vaccinators
and
shoring
up
our
public
health
system
to
move.
Importantly
to
addressing
and
redressing
right.
The
ways
in
which
prioritizing
our
our
healthcare
workers
has
led
to
a
skew
in
the
way
that
our
populations
have
been
served.
B
And
so
that
feels
incredibly
important
and
as
we
move
forward
in
the
the
process
of
transitioning,
what
we
see
that
is
also
going
to
happen
in
this
manchu
in
this
month
of
march
is
a
transition
to
our
third
party
administrator.
B
We
wanted
to
spend
time
in
this
meeting,
taking
a
deeper
dive
with
you
into
the
work
of
the
tpa,
how
we
plan
to
do
our
vaccine
distribution
plan,
and
we
want
to
invite
you
to
share
your
thinking
about
how
we
can
best
implement
and
and
even
improve
on
our
current
plan.
So
you
will
hear
today,
after
an
update
from
dr
pon
on
you
know
how
we're
doing
with
vaccines.
B
You
will
hear
from
marta
greene,
with
gov
ops
from
dr
kimberly
good
with
blue
shield
of
california,
as
well
as
peter
long
at
blue
shield,
about
the
plans
for
implementation
from
our
third
party
administrator,
as
well
as
andy
patterson
from
the
california
primary
care
association
about
the
partnership
and
the
role
with
our
community
clinics.
B
C
C
We
really
wanted
to
have
important
and
useful
and
up-to-date
information
for
you,
and
I
think
you
know
now
that
you've
seen
sort
of
the
announcement
over
the
last
24
to
48
hours.
I
hope
it
makes
more
sense
that
we
wanted
to
to
be
able
to
share
this
really
incredible
progress.
I
think
I
just
want
to
reflect
as
well
as
dr
barcaras
did.
I
think
you
know
we
did
have
a
sombering
moment
very
recently
and
there
are
a
lot
of
anniversaries.
C
You
know
that
continue
to
evolve
and
I
think
we're
coming
up
on
the
anniversary
of
the
first
stay-at-home
order,
which
was
in
mid-march
of
last
year,
and
I
think
you
know
I
do
know
that
that
can
be
triggering
for
some
people
just
about
what
a
long
hard
year
it
has
been.
But
you
know
what
is
really
exciting
is
is
literally
today,
myself
too.
I
just
really
the
light
at
that
end
of
tunnel
is
really
getting
brighter
and
I'm
really
excited
to
share
some
progress
with
you
on
all
of
these
fronts.
C
So
this
is
kind
of
you
know
our
epidemic
curve
as
we
call
it,
and
this
is
all
the
progress
we've
made
as
far
as
decreasing
cases,
so
the
blue
line
is
the
decreases
in
cases,
so
you
see
a
very
steep
decrease
and-
and
I
think
this
is
also
to
help
you
all
see
as
far
as
the
red
line-
and
that
is
the
death,
so
we
still
continue
to
hear
every
day
about
dust,
but
there
is
a
large
time
lag.
So
really,
the
peak
is
still.
C
You
know
much
further
back
in
late
december
during
that
surge.
It
always
is
a
little
bit.
It's
not
only
a
little
bit
behind
the
peak
in
cases,
but
the
reporting
takes
much
much
longer.
Sometimes
we
hear
about
these
final
death
data.
You
know
weeks
later,
so,
while
we're
still
hearing
that
we
really
have
gotten
past
that
are
making
a
lot
of
progress
again
and
then
the
orange
line
is
hospitalizations.
C
We
continue
to
see
those
steep
decreases
in
hospitalizations
and
in
new
admissions,
which
we're
watching
very
closely,
and
then
the
black
line
is
icu,
so
all
of
those
things
are
showing
really
encouraging
trends,
as
is
something
else.
That's
not
on
this
slide,
but
test
positivity,
which
is
another
parameter.
We
look
at
to
really
monitor
the
levels
of
disease
transmission
in
our
community
and
all
of
those
have
a
lot
of
progress.
C
C
Please
and
then
this
is
like
some
incredible
progress.
I'm
really
excited
to
share,
and
you
can
just
see
you
know
really
visually
how
much
we've
ramped
up.
So
you
know
early
on
in
the
in
the
vaccine,
distribution
and
where
we
are
now
and
we
just
hit
a
hallmark.
This
slide
is
already
out
of
date.
We
have
hit
10
million
doses
in
california,
which
is
just
so
exciting,
and
three
million
people
are
fully
vaccinated.
C
So
we've
just
really
come
such
a
long
way
and
really
exciting
and
really
on
our
way
towards
immunity
across
california.
Some
other
things
around
that
are
in
our
over
65
age
range.
We
have
covered
over
23
percent
of
people
that
are
fully
vaccinated
and
that's
about
1.5
million
elderly
over
65,
fully
vaccinated
and,
as
you
can
see
from
this
chart,
our
pace
of
vaccinations
has
dramatically
increased.
C
Recently,
there's
been
over
200
000
doses
per
day
and
weekly
we've
ramped
up
to
you
know,
most
recently,
it's
over
1.6
million
doses
per
week
over
the
past
week.
So
it's
just
continued
to
increase
that
little
dip
in
green
was
when
there
was
the
storms
and
the
delay
and
delivery
of
some
shipments,
and
that's
why
there
was
a
dip.
C
But,
as
you
can
see,
there's
been
a
great
touch
this
week,
so
huge
progress,
but
what
we
have
highlighted
and
what
governor
newsom
highlighted
yesterday
and
what
we
are
continuing
to
be
dedicated
to
work
with
all
of
you
on
is
equity
and
we
have
a
long
way
to
go
there.
We
have
work
to
do
before
we
talk
more
about
that.
C
I
wanted
to
just
review
next
slide,
so
I
know
we
continue
to
have
a
lot
of
questions
and
know
that,
because
there
have
been
changes,
just
wanted
to
re-outline,
again
kind
of
where
we
are
on
who's
eligible
and
how
we're
defining
those
so
early
on
what
we
called
phase
1a
was
our
health
care
workers,
our
long-term
care
residents
and
workers
in
our
skilled
nursing
facilities,
phase
1b
what
was
when
we
opened
up
to
people
65
years
of
age
and
older
and
then
also
will
be
effective,
actually
effective.
C
Now
sorry,
all
of
these
sectors
here
these
top
three
priority
sectors,
which
are
agricultural
and
food,
education
and
child
care
and
emergency
services.
We
have
information
on
our
website
that
kind
of
clarifies
and
has
some
footnotes
on
these
sectors.
They
generally
point
to
what
are
our
essential
infrastructure
workers
that
are
on
the
covet
19
website.
C
So
we
have
details
on
that
and
actually
we're
about
to
update
and
clarify
some
of
those
guidelines
as
well,
so
stay
tuned
for
that,
I
think,
probably
in
the
next
few
days
as
well,
we'll
be
just
sort
of
updating
some
of
the
clarity
on
that
because
I
know
there
are
ongoing
questions
and
and
some
different
interpretations,
so
we're
trying
to
be
responsive
to
a
lot
of
the
questions
that
keep
coming
on
those
areas
and
then
the
next
slide.
Please.
C
And
then
beginning
march,
15th
health
care
providers
can
use
their
clinical
judgment
to
vaccinate
people
who
are
deemed
to
be
the
very
highest
risk
to
get
very
sick
from
covet
19
because
of
several
different
health
conditions.
C
C
Some
of
it
was
the
criteria,
was
clarified
or
narrowed,
because
it
was
a
very
large
number
of
people
until
we
worked
closely
with
our
drafting
guidelines,
work
group
to
clarify
and
define
that
sublist
a
little
bit
further
and
then
also
there's
that
list
of
medical
conditions
and
then,
if
as
a
result
of
developmental
or
other
severe
high
risk
disability,
one
or
more
of
the
following
applies.
C
So
if
the
individual
is
likely
to
develop
severe
life-threatening
illness
or
death
from
kelvin
19
infection
or
acquiring
coping
19
would
limit
the
individual's
ability
to
receive
ongoing
care
or
services
vital
to
their
well-being
and
survival,
and
providing
adequate
and
timely
coveted
care
would
be
particularly
challenging
as
a
result
of
the
individual's
disability,
and
I
think,
a
shout
out
for
a
moment
here
too,
of
again
great
collaborative
work
with
a
lot
of
you
on
this
committee
and
other
stakeholders,
and
I
did
hear
that
another
state
has
adopted
a
very
similar
criteria
for
this,
which
is
always
encouraging
later
today.
C
Our
drafting
guidelines
work
group
is
also
going
to
be
meeting
once
again
to
just
see
if
there's
any
last,
you
know
we
just
heard
again
in
public
comments.
There
have
been
ongoing
requests
to
reconsider
other
medical
conditions
and
or
to
further
clarify
or
define
some
of
these
criteria
so
they're
meeting
again
this
afternoon,
and
we
may
have
some
updates.
C
But
just
wanted
to
clarify
this
list
is
here
as
far
as
and
becomes
eligible
march
15th.
A
lot
of
you
have
had
questions
as
well
about
implementation
of
this,
which
we
know
is
a
challenge
and
one
of
the
ongoing
challenges
that
we're
all
here
to
talk
about
as
well.
We
have
an
implementation
work
group.
That's
also
comprised
of
many
of
you
on
this
committee
as
well.
That
has
been
meeting
around
this
and
really
working
on.
How
do
we
best
implement?
You
know
verification
and
eligibility,
we're
always
trying
to
balance.
C
You
know
upholding
these
criteria
for
priority
of
people
who
really
need
this
vaccine
the
most
and
can
stand
to
benefit
the
most
and
sort
of
you
know
trying
to
balance
not
having
barriers
to
people
or
to
the
operational
aspects
of
getting
vaccine
into
people.
So
that
is
something
that
is
ongoing.
So
before
march
15th
we
will
have
more
updates
on
from
the
state
perspective
and
level
and
what
we're
working
with
with
the
providers
and
the
tpa
on
how
that
eligibility
will
be
verified
and
some
of
the
implementation
aspects
of
that.
C
But
we
know
that's
an
ongoing
question
and
challenge
that.
We're
working
on
and
we'll
continue
to
update
all
of
you
in
the
public
as
that
evolves
next
slide,
and
then
actually
the
last
thing
I'll
say
about
that
last
topic
is,
after
that
you
know
we
were
likely
going
to
be
moving
next
to
the
age-based
framework,
but
again
ongoing
discussions
will
will
always
be
evolving,
and
that
list
also
says,
as
I'm
going,
data
and
science
evolves.
I'm
always
you
know
working
to
make
sure
we're
staying
as
possible,
so
to
shift
gears
for
moment
two.
C
I
think
again.
The
big,
exciting
announcement
that
has
been
made
over
the
last
day
is
that
we
are
really
you
know.
Not
only
are
we
committed
to
equity
as
one
of
our
important
principles?
How
are
we
going
to
make
ourselves
accountable
and
how
you
all
help
us
be
accountable
and
how
we're
going
to
follow
and
monitor
it?
C
So
we've
created
this
vaccine
equity,
metric
or
vaccine
equity
quartile
as
a
critical
indicator
of
how
we're
doing-
and
we
are
you
know-
we
just
really
all
know
and
understand-
that
the
the
greatest
disease
burden
is
in
our
most
in
in
our
most
impacted
communities
is
in.
You
know
we're
using
again
as
a
proxy
our
healthy
places
indexes
we've
used
it
before
for
our
health,
equity
testing
matter
and
again
40
of
the
disease
burden
40
of
the
cases
and
the
deaths
are
in
quartile
one
or
the
lowest
income
quartile.
C
So
we're
going
to
be
monitoring
very
closely.
How
are
we
doing
in
vaccinating
that
quartile
and
how
does
it
compare
to
our
highest
income
quartile?
So
these
are
going
to
be
actually
addressed
as
benchmarks
in
our
blueprint
by
shifting
our
tier
threshold
to
higher
case
rates
once
we
get
to
certain
benchmarks
within
that
vaccine,
equity,
quartile,
so
actually
I'll
walk
through
those
and
I'll
tell
you
where
we
are
in
those
two
next
slide.
C
C
So
when
we
get
to
two
million,
that's
our
goal
number
one
administered,
then
we
will
be
actually
shifting.
The
red
tier
will
become
a
little
bit
more
liberal.
Basically,
so
we
will
be
able
to
more
counties
that
are
sort
of
between
seven
to
ten
will
be
able
to
do
things
that
are
allowed
in
that
red
tier
sector.
C
There
won't
be
changes
initially
to
the
orange
and
yellow
tiers,
but
then,
after
we
get
to
a
next
benchmark
of
four
million
doses
administered
in
our
vaccine
equity
quartile,
then
we
will
be
shifting
down
to
have
some
changes
in
the
orange
and
yellow
and
the
idea.
Again
being
we
know,
we
need
to
get
vaccine
to
our
most
impacted.
That's
our
that's
our
fastest
way
to
actually
move
forward
and
get
out
of
this
pandemic,
and
it's
also
what
we
need
to
do.
C
So
these
are
again,
you
know
the
the
benchmarks
we're
going
to
be
showing
we
actually
just
also
posted
yesterday,
some
graphics
around
that.
So
you
can
see
how
many
doses
you'll
see
that
1.75
million
and
that's
compared
to
over
3
million
in
q4,
so
the
highest
quartile
is
almost
double
the
number
of
doses,
and
we
need
to
fix
that.
C
The
other
graphic
that
you'll
see
on
our
updated
website
on
the
coded
covid19
vaccine
dashboard,
is
that
six
percent
of
the
key
one
that
are
over
16
have
been
fully
vaccinated
and
over
15
with
one
dose,
but
that's
in
contrast
to
13.5
and
27
of
q4.
So
again
we
have
progress,
but
we're
going
to
be
monitoring
it
together
and
doing
all
the
things
that
our
partners
will
be
telling
you
about.
After.
A
C
About
how
we're
going
to
get
there,
I
think
actually,
that
might
conclude
so-
and
I
think
the
last
thing
I'll
say
is
we
are
the
other
things
that
will
be
announced
very
soon.
Probably
later,
today
is
what
are
the
things?
What
are
the
other
refreshes
we're
doing
on
this
blueprint?
What
are
things
that
you
know?
There
are
some
updates,
as
we
think
about
the
science
behind
you
know,
we've
really
really
got
it
now
that
this
is
an
airborne
disease
and
we
really
need
to
continue
to
be
masking.
C
We
have
updated
our
masking
guidance,
you've
heard
about
the
cdc,
double
masking
and
really
fit
and
layers.
I'm
asking
are
the
most
important
especially
indoors,
and
that's
the
other
big
theme
like
we
know
that
outdoors
is
very
low.
Risk
and
indoors
is
higher
risk
they're
really
trying
to
allow
more
things
outdoors,
as
we
all
know
how
antsy
wheel
are,
after
a
year
of
enduring
this
pandemic,.
A
C
Okay,
I
think
I
will
turn
it
over
now
to
to
our
partners
at
blue
shield.
Thank
you.
B
Yes-
and
I
see
lots
of
questions
popping
up
in
the
chat
and
we'll
have
time
some
of
those
questions,
I
think,
will
be
covered
in
part
by
the
presentation
from
marta
and
and
our
partners
at
the
tpa,
but
we'll
have
time
to
get
through
some
of
them
as
we
move
a
little
bit
further
on,
and
so
with
that.
I'd
like
to
go
ahead
and
introduce
marta
green
with
the
california
government
operations
agency
to
share
more
about
equitably,
accelerating
our
vaccine,
distribution
and
administration
for
californians.
E
E
Okay,
so
what
are
we
doing?
Why
are
we
here?
What
are
we
trying
to
deliver?
Some
of
you
have
heard
me
talk
about
this
before,
but
I
just
want
to
kind
of
level
set
again
as
we
talk
about
where
we
are
and
in
the
implementation
of
the
third
party
administrator,
we
are
trying
to
deliver
more
options
to
vaccinate
californians
faster.
We
want
a
big
statewide
network
of
providers.
We
want
it
to
be
geographically
diverse.
E
We
want
to
offer
home
visits
for
those
individuals
that
cannot
leave
their
homes,
mobile
providers
to
reach
hard
to
reach
communities
and
pharmacies
to
reach
many
different
folks.
We
want
more
resources
in
our
communities.
We
want
our
networks
to
be
designed
to
reach
the
most
vulnerable
and
those
disproportionately
impacted
by
covid19
and
the
allocation
methodology
change
that
dr
pond
referenced
earlier.
I
will
get
into
more
detail
because
I
know
there's
been
a
lot
of
questions
about
how
it's
derived.
E
It's
a
it's
a
it's
an
inconsistent
experience
for
californians,
so
we
want
to
have
one
place
that
all
californians
can
go
to,
so
they
know
when
it's
their
turn
to
get
vaccinated
and
they
know
where
they
can
sign
up
for
an
appointment.
We
also
want
to
know
from
the
moment
a
vaccine
is
ordered
to
when
it
enters
the
state
to
when
it
arrives
at
a
provider's
location
and
to
when
it's
administered.
We
want
to
know
everything
about
that
vaccine.
This
is
the
single
most
precious
resource
we
have
in
the
state
of
california.
E
It
is
life-saving,
it
is.
It
is
the
thing
that's
going
to
allow
us
to
open
our
economy
appropriately
and
safely,
and
we
need
to
know
everything
about
it
at
every
moment.
So
we
need
to
have
more
transparency
and
data
into
our
vaccine
distribution,
and
we
need
to
be
able
to
look
at
this
information
daily
and
adjust
our
approach
daily.
So
we
make
sure
we're
hitting
those
targets
that
we
are
in
fact
vaccinating
those
disproportionately
impacted
by
covet
19.,
and
we
want
to
continue
the
ongoing
robust
community
and
stakeholder
engagement
that
has
been
built
today.
E
So
this
is
again
a
little
bit
of
our
problem
statement.
So
it's
this
is
a
few
days
old,
but
you
you
get
the
the
picture.
We
have
a
gap
between
the
doses
reported
as
delivered
to
california
and
the
doses
administered
in
california,
and
some
of
those
are
appropriately
in
freezers
awaiting
upcoming
appointments.
But
we
know
for
a
fact
in
conversations
with
some
of
our
provider
partners
that
those
some
of
these
have
been
administered
and
we
just
lack
the
data
and
without
the
data
we
cannot
judge
ourselves.
E
We
cannot
say
how
well
we
are
doing
against
our
goals
of
equitably
vaccinating
those
most
impacted
by
covet
19..
Also,
as
a
result,
first
dose
allocations
to
california
have
been
completely
flat.
We
are
not
seeing
significant
increases
in
supply
other
than
the
one-time
increase
of
the
new
yanson
or
janssen
or
johnson
and
johnson.
I've
heard
it
referred
to
so
many
different
ways,
but
the
new
vaccine
we
have
a
one-time
bump
coming
in.
E
We
do
not
have
anticipated
allocations
for
that,
but
other
than
that
we
have
been
entirely
flat
and
we
have
to
be
able
to
demonstrate
to
the
federal
government
our
capacity
to
be
able
to
equitably
and
quickly
administer
vaccines
in
order
to
ensure
that
our
our
supply
continues.
So
again,
we
want
to
hit
our
our
equity
goals.
We
want
to
hit
our
speed
goals,
but
we
want
to
hit
our
speed
goals
in
vaccinating
the
right
people
and
the
right
people
are
those
most
likely
to
be
impacted
and
most
disproportionately
impacted
by
covet
19.
next
slide.
Please.
E
So
you
know
there
was
announcement
and
you
know
there
was
a
lot
of
talk
about
march
1st
and
I
think
it
it
caused
some
people
to
say
well
what
really
changed
on
march
1st.
Well,
some
things
changed
that
were
important
and
some
things
didn't
change.
There
was
absolutely
no
light
switch
change.
On
march
1st
to
the
current
vaccination
network.
All
providers
that
were
currently
in
the
system
and
able
to
vaccinate
were
going
to
continue
to
be
in
the
system
to
vaccinate.
E
So
we
were
starting
to
make
recommendations
regarding
vaccine
allocation
to
providers
in
part
based
on
how
well
they
were
performing
and
administering
vaccine
and
then,
as
you
heard,
the
the
governor
announced
yesterday,
we
oh
no.
My
days
are
running
together,
but
you
heard
the
number
the
governor
announced
recently.
The
way
we
switched
vaccine
allocation
methodology
to
really
concentrate
those
doses
in
the
lowest
quartile
hpi
tracks
and
we
developed
that
allocation
methodology
and
partnership
and
really
led
by
our
colleagues
at
the
department
of
public
health,
but
also
working
closely
with
our
colleagues
at
blue
blue
shield.
E
So
we're
going
to
be
working
with
our
existing
provider
network
to
get
get
in
a
contract
in
order
to
agree
to
join
my
turn
and
perform
in
our
performance
management
system,
where
blueshield
is
working
closely
with
every
local
health
jurisdiction
to
create
an
in-depth
transition
plan
to
ensure
that
this
is
smooth,
because
we
do
not
want
any
bumps
in
the
system.
We've
got
many
things
in
in
the
in
the
the
current
vaccination
system
that
are
working
well,
and
we
want
to
continue
to
support
those.
E
E
So,
as
I
talked
about,
we,
we
kind
of
have
carved
the
state
into
waves
for
onboarding,
and
we
looked
at
a
number
of
different
factors
about
how
we
were
going
to
decide
which
counties
to
onboard
first
and
we
actually
came
up
with
a
relatively
thoughtful
and
scientific
approach
of
how
we
prioritize
the
counties
and
we
looked
at
basically
five
factors.
We
looked
at
the
percentage
of
the
population
that
was
living
in
the
lowest
quartile
right,
so
we've
been
talking
about
how
it
how
important
it
is
to
target
this
population
because
of
their
disease
burden.
E
We
looked
at
the
percentage
of
the
population
that
was
eligible
to
be
vaccinated.
We
looked
at
the
coven
19
cases.
As
a
percent
of
the
total
population,
we
looked
at
cova
19
deaths
as
a
percentage
of
the
total
population,
and
then
we
looked
at
the
vaccine
administration
data
and
with
that
we
were
able
to
rank
the
counties
and
then
bucket
them
into
waves.
E
E
So
this,
I
won't
spend
a
lot
of
time
here,
but
here's
our
waves,
we
started
with
a
smaller
chunk
that
had
some
of
the
higher
case
rates
that
had
some
of
the
lower
vaccination
rates.
We
are
pretty
close
to
being
done
with
wave
one
in
the
onboarding
process.
We
are
working
heavily
right
now
in
the
wave
two
counties
working
closely
with
our
local
health
jurisdictions
on
those
transition
plans,
as
I
mentioned
that
include
a
significant
equity
component
next
slide.
Please.
E
So
this
is
an
example,
and
this
is
again
a
few
days
old,
but
this
is
kind
of
where
we
were
and
how
we
are
thinking
about
our
network
development.
So
this
is
fresno,
so
this
is
one
of
our
wave
one
counties
and
how
we
looked
at
geographic
access
and
the
different
providers
that
were
available
to
us,
and
so
we
were
able
to
identify
with
those
that
were
in
contract
and
we
were
in
the
process
of
contracting
with
that.
E
We
actually
had
an
area,
a
populated
area
in
fresno
that
we
didn't
have
access
and
you'll
see
that
it's
a
slightly
purple
little
little
purple,
splotch
there
so
in
working
with
our
partners
in
the
local
health
jurisdiction.
This
is
where
we
come
up
with
some
innovative
strategies
to
reach
that
area,
because
we
do
not
have
adequate
access,
and
so
this
is
where
we
would
consider
the
type
of
pop-up
clinics,
the
mobile
clinics
that
we
can
bring
to
bear
to
this
community
to
ensure
that
they
have
access
to
this
really
important
vaccine
next
slide,
please,
okay!
E
So
this
is
the
big
change
this
week,
so
I'm
going
to
spend
a
little
extra
time
on
the
slide
and
and
and
how
the
the
calculations
work,
because
there's
been
a
ton
of
questions.
So
this
is
how
allocation
beginning
in
the
allocation
decisions
that
were
made
this
week.
This
is
how
it
works.
So
the
first
thing
that
we
do
is
we
have
to
take
a
certain
number
of
doses
off
the
top,
because
we
have
certain
patient
populations
that
the
state
is
directly
in
charge
of
those
are
those
living
in
state
hospitals
and
correctional
institutions.
E
This
is
not
very
large
amounts,
but
we
do.
We
do
take
those
off
the
top.
We
then
have
to
prioritize
clinically
very
important
things
like
unmet
need
for
second
doses,
so
this
is
when
a
patient
has
reached
the
three
week
limit
or
the
four
or
the
three
week
or
four
week
time
frame,
depending
on
which
vaccine
they've
has
been
administered
and
there's
no
second
dose
for
them,
and
so
we
have
to
prioritize
those
so
that
those
individuals
finish
their
their
vaccination
corsa
treatment
and
we
ended
up
with
some
second
dose
shortages
throughout
california.
E
That
needed
to
be
addressed
most
urgently
over
the
next
over
the
this
week
in
the
upcoming
week.
So
once
we
deal
with
those
kind
of
unmet
and
urgent
issues,
we
then
take
the
pool
of
vaccine
and
we
apply
a
geographical
weighting,
and
this
is
what
we've
always
done.
So
this
has
been
the
approach
that
we've
had
since,
even
when
we
were
doing
1a
but
we're
doing
it
with
the
population
that's
eligible
today.
E
So
we
look
at
the
over
65
population
plus
the
three
sectors,
the
first
responders
food
and
agriculture
and
education
and
child
care.
We
weight
that
70
towards
the
over
65
population
and
30
percent
towards
education
and
child
care.
So,
with
80
of
the
doses
we
spread
those
by
zip
code
by
eligible.
So
if
zip
code
x
has
one
percent
of
the
eligible
people
based
on
this
formula,
they
will
get
one
percent
of
that
eighty
percent
pool
of
the
vaccine,
so
we
just
spread
it
evenly,
and
I
call
this
the
even
layer.
E
E
E
As
the
state
establishes
more
direct
contracts
in
each
jurisdiction,
there
will
be
more
transparency
into
exactly
which
providers
within
that
jurisdiction
are
receiving
that
vaccine
and
we'll
be
able
to
do
a
better
job
at
targeting
directly
to
the
zip
codes
that
we're
trying
to
reach
and
sending
doses
exactly
to
those
locations
over
time,
we
will
continue
to
adjust
as
supply
increases,
especially
be
able
to
adjust
those
those
allocations.
E
So
that
we're
maximizing
the
provider
performance,
especially
in
those
lowest
quartile,
hpi
tracks
and
last
but
certainly
not
least,
second
doses,
automatically
follow
first
doses
and
they're
actually
sent
out
on
a
second
different
time
frame,
so
on
tuesdays,
generally
speaking,
is
when
allocations
are
posted
for
first
doses,
the
second
dose
allocation
process
happens
on
sunday.
This.
This
whole
allocation
methodology
only
applies
to
first
doses,
because
second
doses
follow
those
first
doses
to
whichever
provider
provided
the
first
dose
next
slide.
Please.
F
Well,
thank
you
martha
and
good
afternoon.
Everyone
I'm
kimberly
good,
and
I
am
the
senior
vice
president
of
external
affairs
for
blue
shield,
and
I
also
serve
as
our
chair
of
our
diversity,
equity
and
inclusion
leadership,
council
and
I
get
to
co-lead
our
equity
practice
with
my
colleague
peter
long
who
you
will
hear
from
in
just
a
moment.
F
F
We
work
really
closely
with
all
of
our
state
partners
and
local
health
jurisdictions
to
ensure
that,
as
you've
already
heard,
we
are
building
on
what
has
already
existed
to
ensure
that
we
optimize
the
current
network
and
offerings
as
we
seek
to
expand
it
and
accelerate
the
work
that
we're
doing
our
goals
in
this
process
to
is
is
to
ensure
that
we
are
building
on
what's
working
well
and
that
we
work
together
to
identify
those
things
that
will
enhance
how
we
allocate
and
support
the
vaccine
process
under
the
direction
of
our
state
partners.
F
We
want
to
make
sure
that
we
are
fully
embracing
what
everyone
on
this
call
is,
which
is
to
ensure
that
we
save
more
lives
and
that
we
do
that
in
a
way
that
is,
that
is
equitable.
That's
going
to
require
us
to
use
more
data
and
to
also
tap
into
the
expertise
of
those
on
the
ground,
and
that's
why
we're
being
so
diligent
in
how
we
approach
this
work
with
lots
of
points
of
connection,
everyone
has
been
very
generous
with
their
feedback.
F
We
appreciate
it
and
we
are
taking
doing
meetings
with
every
single
local
health
jurisdiction
and
a
number
of
other
stakeholder
groups.
If
we
go
to
the
next
slide,
this
will
really
illustrate
for
you
what
we
mean
by
this
being
a
build.
This
five-point
plan
should
be
very
familiar
to
the
group.
We
didn't
create
it.
We
have
embraced
it
as
part
of
the
state's
approach
to
how
we
are
approaching
vaccine
equity
and
just
as
we
do
as
a
company
where
we
embed
a
diversity,
equity
and
inclusion,
focus
and
everything
we
do
at
blue
shield.
F
F
Tpa
perspective
as
it
relates
to
each
of
these
five
points
on
the
allocation
side
certainly
will
be
using
the
data
to
make
recommendations
to
the
state
really
important
that
we
all
have
a
clarity
that
the
final
allocation
decisions
will
be
a
state
decision,
but
certainly
we
will
be
supporting
all
of
those
efforts
to
ensure
that
our
equity
goals
are
met,
whether
it's
through
the
prioritized
approach
for
the
allocation,
as
well
as
any
other
expectations
set
by
the
state
you
know
most
of
our
energy
is
really
focused
on
making
sure
that
we
enhance
the
network
as
you've
heard.
F
There
are
no
changes
to
the
network
today
and
I'll
talk
about
some
of
the
progress
that
we
have
in
the
transition.
But
ultimately,
our
goal
is
to
make
sure
that
we
have
a
very
robust
network
provider
network
that
helps
us
achieve
our
goals
and
certainly
helps
us
reach
all
of
the
hard-to-reach
populations
that
are
important
to
us,
as
we
think
about
the
compute
community
partner
section.
F
That's
not
an
area
that
we're
accountable
for,
but
we
are
in
partnering
with
our
state
partners
to
ensure
that
we
have
the
necessary
outreach
and
support
for
organizing
for
communities
that
are
disproportionately
affected,
the
same
with
public
education.
Again,
that's
a
partnership
piece
where
we're
not
taking
the
lead.
We
certainly
do
have
a
role
with
regard
to
timely
data
and
analytics,
as
you
heard
marta
describe.
F
So
we
certainly
will
be
playing
a
lot
of
goals
there
from
a
principal
perspective.
We
intend
to
be
transparent
and
making
sure
that
that
data
is
as
accurate
and
that's
one
of
the
reasons
that
you
have
had
the
the
big
push
on
my
turn,
because
having
that
a
single
place
where
information
is
coming
in
and
housed
will
enable
us
to
be
accurate
and
timely
in
that
data,
if
we
go
to
the
next
slide
very
quickly,
because
I
know
that
bobby
said,
we
have
we've
run
a
tight
ship
here.
F
Here's
some
points
of
progress
for
us.
In
our
first
wave
we
announced
when
we
talked
about
the
transition
that
there
are
three
waves
and
there
is
a
whole
process
of
determining
how
we
prioritize
counties.
In
essence,
we
were
prioritizing
counties
where
we
saw
the
greatest
need
for
us
to
get
in
and
try
to
close
gaps
and
enhance
what's
there,
so
we
have
met
with
all
of
the
wave
one
counties
and
we've
already
secured
about
a
thousand
sites
that
are
in
that
network.
F
We
have
all
the
multi-county
entities
contracted,
except
for
one
and
this
changes
by
the
hour.
So
who
knows
where
things
may
be?
At
this
point,
we've
got
additional
optum
locations
that
are
identified
wave.
One
fqs
are
under
contract,
those
that
are
currently
vaccinating
and
we're
also
finalizing
very,
very
close
to
finalizing
the
details
with
homebound
and
other
providers
to
serve
the
disabled
community
and
then.
Lastly,
here,
as
we
mentioned
before,
we
are
working
very
closely
with
all
of
the
local
health
jurisdictions,
in
particular
in
particular,
on
equity
plans.
F
G
F
F
Yep
and
I'll
go
we'll
keep
it
moving
here.
This
is
peter's
favorite
slide,
so
I'm
so
sorry
that
his
dog
interrupted,
but
this
is
just
an
overview
of
sort
of
a
pictures
worth
a
thousand
words.
F
So
the
the
the
goal
here
is
to
show
what
the
coverage
would
look
like
from
a
network
perspective,
as
well
as
identifying
the
partnership
between
statewide
organizations,
regional
organizations
that
serve
multiple
counties,
those
that
serve
north
northern
california-
and
this
is
an
example
of
the
kind
of
data
that
we
want
to
be
able
to
gather
and
show
so
that
we
have
a
complete
and
integrated
approach
to
delivering
vaccines
in
an
equitable
way.
F
Just
shows
again
how
this
is
an
iterative
process,
and
it's
not
something
as
you
all
have
that
have
been
in
this
game
since
it
started
understand.
This
is
not
something
that
is
once
and
done.
It's
iterative
data
evolves
circumstances
around
the
virus
evolve,
so
we
want
to
make
sure
that
we
have
an
iterative
process
that
is
well
coordinated
and
dynamic
to
meet
the
needs
of
the
communities
that
we're
trying
to
reach,
and
we
know
that
that's
going
to
rely
on
feedback
mechanisms
and
that's
what
we're
trying
to
illustrate
here.
F
A
lot
of
this
work
is
not
under
the
direct
control
of
the
tpa,
but
it
is
a
partnership
that
we
do
with
our
colleagues
in
cdph
and
on
the
state
side,
so
that
all
the
great
work
that
they
are
doing
to
from
a
public
education,
a
cbo
perspective.
The
recent
cohort
that
was
just
announced
we
together
are
making
sure
that
all
of
that
is
harmonized
in
a
way
that
achieves
our
goals.
F
The
next
slide,
which
is,
I
believe,
our
last,
is
really
just
a
way
of
reiterating
what
we've
said
multiple
times.
Our
commitment
is
to
be
a
partner
in
the
process.
We
know
that
there
is
a
there
are
a
lot
of
questions,
there's
a
lot
of
speculation
and
concern.
F
I
will
simply
say
to
you
that
blue
shield's,
only
interest
in
being
in
this
process
is
to
exhibit
our
care
and
concern
for
the
health
and
well-being
of
californians,
and
we
are
committed
to
partnering
with
all
of
you
and
our
our
state
colleagues,
to
do
all
that
we
can
to
help
get
behind
this
pandemic
so
that
we
can
restore
our
our
state
and
our
economy
to
where
we
want
it
to
be.
So
I
think
that's
our
final
slide
and
with
that
I
think
bobby.
A
I
think
before
we
go
there,
we
have
andy
patterson
from
the
california
primary
care
association
to
talk
a
little
bit
about
how
the
federally
qualified
health,
centers
and
other
community
clinics
are
going
to
be
involved
in
vaccine
distribution.
So
we'll
go
to
the
next
slide
and
andy
welcome
great.
Thank.
H
You
so
this
is
on
the
federal
but
I'll
just
comment
really
briefly
on
the
the
blue
shield
partnership.
So
we
were
we're
we're
talking
all
the
time,
and
I
thank
the
blue
shield
team
for
allowing
me
to
hound
the
many
staff
that
you
have
working
on
this
and
I
think
we
are
making
lots
of
connections.
H
We
are
we're
working
to
try
to
ensure
that
every
clinic
and
fqhc
that
wants
to
continue
to
vaccinate
and
participate
in
this
effort
can
do
that,
and
so
we
are
cbca
is
helping
to
make
sure
that
all
those
connections
are
made
and
appreciate
the
blue
shield
team
for
really
doing
everything
that
they
can
to
make
sure
that
that
happens.
H
We
have
yet
to
fully
resolve
the
issues.
With
my
turn,
I
think
there's
lots
of
it's
a
absolutely
I'm
kind
of
a
tech,
geek
and
policy
love
the
vision
it's
really
hard
to
implement,
so
we're
working
through.
All
of
that,
I'm
sure
everyone
knows
that
not
all
health
centers
use
the
same
system,
though
our
best
efforts
to
try
to
make
that
happen
many
years
ago,
then
you
have
to
try
to
adapt
those
systems
to
new
technologies,
we're
all
using
different
versions
of
different
emr.
H
Fqhcs,
like
pharmacies
are
getting
a
direct
allotment
and
we're
really
excited
that
the
biden-harris
administration
is
taking
advantage
of
this
amazing
federally
qualified
health
center
system
and
indian
health
center
and
indian
health
services
system
that
our
country
has
invested
in
and
there
are
over.
You
know
fqhc's
are
serving,
I
think,
about
30
million
30
million
people
in
the
in
the
country
right
now
and
we
are
going
to
leverage
them
so
today,
you'll
see,
I
won't
walk
through
the
numbers,
but
five
of
the
first
25
in
this
program.
It's
not
a
pilot.
H
It's
a
program
we're
in
california
and
they're,
the
choices
of
which
fqhcs
were
participating.
First
were
really
based
on
special
populations,
so
ag
and
homeless.
Of
particular
note,
more
and
more
health
centers
are
going
to
be
onboarded.
They,
the
wave
2
cohort,
has
started
to
re,
receive
vaccines,
wave
3
has
ordered
and
but
has
yet
to
receive
any.
H
So
we'll
start
seeing
this
happen,
the
state
we're
all
aware
of
this
we're
trying
to
triangulate
whether
or
not
how
to
integrate
what's
coming
in
from
the
feds
with
what
the
state
can
see
that
the
state
is
getting.
H
The
focus
of
all
of
this
equity
work
and
yes,
we
will
be
health,
centers
can
get
the
pfizer,
but
only
the
very
few
have
the
cold
storage
most
are
getting
moderna
and
then
j
and
j
will
be
coming
out,
and
I
believe
that
there
is
ability
to
choose
when
they
start
ordering.
So
just
wanted
to
acknowledge
that
is
happening,
and
we
are
really
excited
about
the
opportunity
to
participate
in
ending
the
pandemic
quickly.
Thank
you
bobby.
B
Thank
you
so
much
andy
and
for
that
highlight
on
the
vital
partnership
with
our
federally
qualified
health
centers,
and
now
I
want
to
jump
into
some
q
a
so
we
can
have
bobby
facilitate
that,
and
let's
start
with
two
questions
that
I
know
off.
The
bat
are
from
marta.
B
B
And
then
the
second
question
for
marta
is
were
some
of
the
the
some
health
centers
were
reporting
reductions
in
supply
recently?
Is
that
due
to
the
tpa
or
is
that
something
else.
E
Sure
so
I'll
take
the
the
first
one
first
and
the
second
one,
second,
so
the
first
one.
So
when
we
originally
started
this
project,
we
thought
that
pay
for
performance.
You
know
having
some
sort
of
incentive
payments
for
reaching
targets
was
the
way
we
were
going
to
be
able
to
achieve
our
goals
and
what
we've
realized
that
that's
not
really
it
what's
it.
What
is
it
is
that
providers
need
support
to
reach
our
target
communities,
and
so
what
we're
doing
as
part
of
the
onboarding
process
is
providers
can
basically
say
here's
my
plan.
E
I
want
to
help
you
reach
your
target
communities.
Well,
we're
talking
about
the
lowest
quartile
hpi
tracks,
whether
we're
talking
about
hard
to
reach
communities
in
some
other
capacity,
whether
we're
talking
about
farm
workers,
whether
we're
talking
about
people
with
disabilities
and
here's
my
plan,
but
what
I
need
in
from
you
state
of
california.
In
order
to
support
that
is,
I
need
resources
to
support
these
additional
staffing.
E
These
additional
physical
costs
and
the
state
is
has
built
a
process
and-
and
we've
talked
about
this,
as
as
part
of
our
plan
to
up
fund
up
front
those
costs
to
allow
those
providers
to
get
into
the
community
long-winded
answer
of
saying
that,
yes,
targeting
people
with
disabilities
and
those
with
comorbid
medical
conditions
is
one
of
the
the
things
that
we
can
fund.
E
Second
question:
oh
remind
me,
dr
burkharis,
I'm
so
sorry,
oh,
it
was
reductions
in
allocation
to
fqhcs.
That's
what
it
was
yes
so
week
over
week,
so
the
allocation
decisions
that
went
out
this
week
from
the
week
prior
for
local
health
jurisdictions,
they
were
flat
or
up.
They
were
they're
flatter
up.
Nobody
went
down,
however.
E
What
I
will
say
is
the
mix
of
vaccine
changed,
so
we
we,
we
had
lots
of
of
local
health
jurisdictions
that
received
either
less
pfizer
or
less
moderna
or
less
of
both
and
j
and
j.
So
I
can't
speak
to
what
happened
to
these
specific
fqhcs
or
community
clinics
that
may
have
received
less,
but
I
can
suspect
that
if
the
mix
changed
and
they
were
receiving
one
of
the
different
vaccine
types-
that
it
is
possible
that
because
the
mix
changed
when
they
were
sub-allocated,
some
something
could
have
changed
in
that
regard.
E
A
Okay,
thank
you,
martha
really
great
to
get
your
feedback
on
these
issues,
so
we're
going
to
start
with
dr
jeffrey
luther
and
then
we'll
go
to
dr
david
lown
and
then
we'll
go
to
kieran,
danny
ronnie
and
erin.
So
that's
where
we'll
start
just
so.
You
know
where
you're
coming
and
then
we'll
see.
If
we
can
get
to
everybody
else,
that's
interested
in
questions
make
sure
to
introduce
yourself.
I
Thanks
bobby
I'm
jeff
luther,
representing
the
california
academy
of
family
physicians,
my
concern
has
to
do
with
prioritization
among
the
16
to
65,
with
comorbid
conditions
group
we're
already
in
my
practice,
getting
phone
messages
and
emails.
Saying
hey
doc.
I
have
asthma,
I'm
obese.
When
do
I
get
my
shot?
Or
can
you
send
me
a
letter
so
that
somebody
who's
giving
out
shots
will
know
that
I
deserve
one
and
we're
getting
lots
of
messages
from
our
constituents.
I
Family
physicians,
around
the
country
and
from
our
our
parent
organization,
that
the
the
prospect
for
a
deluge
of
patient
communicates
kind
of
taking
over
the
work
day
in
in
place
of
patient
care
time
is
has
a
lot
of
docs
worried.
So
our
concern,
my
concern
would
be
that
as
this
is
trotted
out
and
as
we
have
delineated,
what
those
qualifying
conditions
are.
C
Sure,
that's
fine.
I
think
you
know
I
did
try
to
mention
this
when
I
was
talking
about
the
different
conditions
and
that
we
have
an
implementation
implementation
work
group,
that's
working
really
hard
on
this.
We
know
this
is
a
concern
and
an
issue,
and
you
know
we've
seen
some
templates
from
our
local
health
department.
C
Colleagues
about
eligibility,
but
but
we
know
this
is
a
concern
and
you
know
I
think
we
do
have
a
couple
more
weeks
to
or
well
I
guess
it's
only
10
days,
but
so
we're
working
hard
on
that
and
there
will
be
more
communications
coming,
but
we
have
a
stakeholder
group
about
implementation
with
again
many
crossover
from
people
on
this
committee
as
well
so
stay
tuned
on
that
thanks.
J
Hi,
thank
you.
This
is
david
lown
from
the
california
association
of
public
hospitals
and
health
systems,
quick
question
for
you,
marta
did
what
you
describe
in
terms
of
the
support
systems
to
providers
to
meet
the
equity
goals
with
plans
and
then
requested
support.
Does
that
mean
that
there
will
not
be
p4p
incentives
or
are
or
is
that
a
or
p5p
incentives
on
a
separate
track?
And
if
so,
what
are
the
details
on
those
incentives.
E
So
we
still
have
room
in
the
contract
to
develop
specific
pay
for
performance
incentives,
but
to
be
so
a
couple
of
things,
number
one
they're,
not
female
reimbursable,
because
fema
looks
at
the
administration
of
the
vaccine
as
the
reimbursement,
and
so
that's
one
issue.
The
second
issue
we
have
is
everybody
wants
the
vaccine
right
now
there
is
no
provider.
That
is
saying
to
me.
E
Don't
give
me
an
allocation,
and
so
it
appears
to
to
us
at
this
moment
that
really
what
we
need
to
be
doing
is
giving
them
the
support
that
they
need
in
order
to
administer
more
of
it
right,
administer
more
of
it
to
the
right
people
or
administer
more
of
it
to
the
right
people
in
the
right
places.
So
that's
why
we
really
think
the
effort
is
better
spent
in
these
upfront
costs
to
allow
providers
to
get
mobile
to
allow
providers
to
do
in
home
to
allow
providers
to
to
reach
those
communities,
as
opposed
to
saying.
E
Well,
since
you
vaccinated
10
people
in
a
zip
code,
that's
what
we're
paying
I
just.
We
don't
see
that
as
the
most
effective
approach
to
reach
our
target
communities.
We
really
want
to
target
it
towards
getting
the
vaccine
to
the
people
that
we
really
want
to
get
vaccinated.
That's
why
we
think
the
upfront
payments
are
a
better
strategy.
E
A
K
Karen
sure
I'll
be
really
quick,
kieran,
savage
california,
pan-ethnic
health
network.
I
don't
have
a
question.
I
actually
just
want
to
offer
my
gratitude
appreciation
for
the
really
strong
I
think,
move
towards
equity
yesterday
or
the
day
before
I've
lost
track
of
time.
I
think
you
know.
I
feel
that
when,
when
you're
critical
in
so
many
meetings
about
the
equity,
you
you
have
to
give
the
praise
we're
due,
and
I
really
do
appreciate
it,
and
I
know
there's
a
lot
to
be
worked
out
in
the
implementation
to
really
see
the
results.
K
L
All
right,
hi,
everyone,
benny
chan
from
justice
and
aging.
I
have
one
question
followed
by
a
couple
of
points
that
I
want
to
make.
H
L
The
first
is
to
echo
what
kieran
said:
thank
you
to
the
state
for
really
putting
its
money
where
its
mouth
is
or
its
allocation,
where
its
mouth
is
in.
The
40
decision
will
hardly
support
that
and
appreciate
it
greatly.
Two
process
points
before
I
get
to
my
question.
One
is
I
I
believe
at
the
one
of
the
previous
cvec
meetings.
L
We
had
said
that
we
wanted
heads
up
on
policy
changes
and
would
just
reiterate
that
heads
up
to
the
extent
that
you
can
do
it,
it
would
be
really
helpful
to
find
out
through
things
as
a
member
of
the
cvac
and
not
on
the
evening
news
and
then
two
to
the
extent
that
we
have
lots
of
things
to
talk
about
as
we
are
rolling
this
out.
As
I
know
we
do
and
why
the
agendas
are
so
cramped.
L
I
would
be
in
favor
of
actually
going
back
to
three-hour
meetings.
If
it
means
we
can
actually
do
a
deeper
dive
on
some
of
these
issues.
I
understand
that
there
are
long
meetings,
but
I
think,
with
an
appropriate
amount
of
a
break,
it
allows
us
to
better
leverage
each
other
in
terms
of
learning
what
the
state
is
doing
and
giving
feedback.
So
those
are
two
process
points.
My
question
really
is
about
data
related
to
older
adults
of
color.
L
This
is
a
point
that
I
feel
like
I've,
become
a
broken
record
on
that
I
think
is
really
important.
The
administration
has
said
they
want
to
learn
fast
and
learn
quickly
in
responding
to
the
copenhagen
crisis.
South
carolina
and
washington
are
ahead
of
the
game.
They've
already
learned
and
they're,
giving
the
public
vaccination
rates
broken
out
by
age
and
by
race
intersectionally
both
of
those
factors
combined.
L
So
my
hope
is
that,
in
moving
to
the
tpa
one
of
my
understandings
is
that
we
would
get
better
data
and
faster
data.
I
saw
in
the
fact
sheet
that
was
released
earlier
this
week
that
there
is
a
commitment
to
do
it.
So
my
question
is:
when
can
stakeholders
expect
to
get
that
data.
E
I'll
start
with
that,
one
so
part
of
the
transition
that
we're
going
through
right
now
is
bringing
all
of
those
providers
on
to
that.
My
turn
system
that
is
going
to
give
us
that
real-time
transparency,
so
it
is
a
process
I
wish
I
wish.
I
could
snap
my
fingers
and
all
providers
would
be
on
the
system
and
we
would
have
that
level
of
transparency
to
the
data
right
away.
E
It's
just
it's
a
little
bit
more
of
a
process,
so
I
think
at
the
last
time
I
checked
we
had
1600
unique
sites,
statewide
that
were
that
were
actually
in
contract
and
we're
in
the
process
of
working
through
getting
all
of
those
folks
onboarded
into
my
term,
and
when
that
happens,
that
is
a
that
system
is
integrated
with
myca-vax
and
the
different
inventory
management
and
ordering
systems
that
we
have
all
the
way
to
the
back
end
to
the
the
vaccine
registry,
and
so
what
that'll
allow
us
to
do
is
for
every
provider
that
is
in
the
network
and
on
my
turn,
we
know
when
the
vaccine
is
in
transit
to
the
provider
when
it's
sitting
at
the
provider
when
it's
administered.
E
So
we
will
be
able
to
see
that
and
who
it's
administered
to
so
for
those
network
providers
we
will
be
able
to
provide
much
greater
granularity
of
data
than
than
what
is
available.
Today,
however,
we
do
have
some
rich
data
already,
and
there
is
a
lot
of
data
in
the
the
existing
vaccine,
administration
system
or
databases.
We
just
know
that
we're
missing
chunks
of
it,
we
know
that
there
are
is,
is
vaccine
that
has
been
administered.
L
C
I'll
sort
of
respond
I
mean,
I
think,
actually
so
again,
the
hpi
data
finally
went
up
yesterday,
and
I
think
that
is
our
next
step
that
we're
absolutely
talking
about,
like
you
know,
on
an
ongoing
basis.
So
again,
just
acknowledging
we've
had
a
lot
of
data
challenges
with
the
decentral
decentral
process
of
our
health
care
systems
and
our
you
know.
So
I
think,
as
this
has
been
kind
of
a
challenge,
all
along
of
getting
good
data.
I
will
actually
just
I
saw
in
the
chat
as
well
people
asking
about
the
sexual
orientation
gender
identity.
C
I
can
also
say
that
there's
a
lot
of
just
behind
the
scenes
issues
around
the
way
data
is
transferred
between
electronic
health
records
and
other
data
systems.
We've
had
a
challenge
with
that
data,
even
for
cases,
so
we
have
a
huge
chunk
of
that
missing
and
it's
a
very
national
technical
issue
around
how
data
is
transferred
in
hls7
messages,
but
we
are
planning
even
before
during
this
transition
to
start
to
post
more
by
race
and
ethnicity,
so
we're
just
kind
of
trying
to
do
this
in
a
stepwise
fashion.
C
We
have
something
that
looks
really
different.
We
want
to
try
to
validate
so
we've
been
working
really
hard
on
that
behind
the
scenes
and
we
may
have
something.
You
know
we're
hoping
to
have
something
much
sooner
to
that
point,
but
we're
very
excited
again
that
we
at
least
have
our
hpi
metric
and
we're
doing
that
by
hp,
which,
as
you
know,
correlates
quite
well
with
that,
but
now
we're
trying
to
cross-section
all
that
so
continuing
to
work
on
our
data
and
and
posting
on
that.
C
A
And
thanks
danny
for
the
process
points.
We
are
definitely
have
those
two
issues
top
of
mind
and
have
been
talking
about
both
as
we
try
to
push
data
and
information
out
to
you
as
quickly
as
possible,
and
we've
been
talking
about
the
meeting
time
again.
So
thank
you.
So
let's
go
on
to
ronnie
and
then
we'll
go
to
aaron
and
we're
gonna
extend
our
time
for
this
section,
just
a
teeny
bit.
A
So
we
can
take
a
few
more
comments
and
then,
if
we
have
more
time
later,
we'll
come
back
because
I
see
everyone
who's
wanting
to
talk
in
the
next
section
and
we
won't
get
to
everyone
so
go
ahead.
Ronnie
and
then
aaron
don't
forget
to
introduce
yourself.
M
Thanks
bobby
ronnie
kelly
county
behavior
health
directors
association,
this
is
really
a
point
of
clarification.
I'm
asking
for
dr
pawn
referenced
to
check
back
on
the
priorities
and
then
marta
in
your
slide
number
23.
It
talks
about
finalizing
details
on
options
for
homebound
and
disabled
californians.
E
M
Special
right,
I
know
dr
aragon
said
that
we
would
address
this
gap
that
that
people
who
have
a
serious
mental
illness,
in
particular
those
with
schizophrenia
having
the
second
highest
morbidity
behind
a
mortality
rate
behind
age,
that
we
are
going
to
be
able
to
call
out
behavioral
health,
serious,
mentally
ill
and
substance
use
disorder.
Folks,
as
disabled
individuals,.
C
A
Yeah,
that's
at
the
top
of
the
agenda
for
directing
guidelines
today,
ronnie,
let's
go
on
to
aaron.
G
Thanks
so
much
bobby
and
thank
you,
dr
burke,
harrison
pond
for
all
the
work.
Thank
you
to
the
state
for
its
continued
commitment
to
equity.
What
was
announced
this
week
really
was
a
creative,
inclusive
revolutionary
and
I'm
glad
that
the
states
other
states
are
noticing
how
california
is
doing,
what
they're
doing
and
taking
tips
where
they
can,
including
south
carolina,
using
some
of
california's
language
around
developmental
and
other
disabilities.
So
thank
you
for
your
leadership
and
how
it's
leading
us
here
and
spreading
to
other
states
two
pieces
of
feedback.
G
One
is
that
we're
hearing
comments
from
the
community
of
people
having
long
waits
to
get
through
my
turn,
whether
they're
on
they
get
timed
out
at
the
portal
or
they're
on
the
phone?
So,
if
you
can,
please
monitor
and
staff
up
to
meet
the
response.
That's
coming
thanks.
Marta
see
nodding,
appreciate
you
got
that
one
also.
G
Second,
regarding
communications,
we're
really
gonna
need
something
that
just
explains
clearly
to
the
public:
here's,
how
you
get
a
vaccine,
there's
multiple
routes
and
and
just
something
plain
and
simple
that
just
says:
okay,
I
I'm
eligible.
I
need
it.
I
want
it.
Here's
how
I
go
to
get
it.
G
My
question
is
so
that's
a
suggestion.
My
question
is
that
we're
in
a
time
of
scarcity
and
we're
building
a
system
during
a
time
of
scarcity,
but
soon
there
will
be
abundance.
G
The
end
of
may
is
is
not
that
long
away.
What
are
the
projections
to
see
what's
coming
into
the
state,
so
we
start
moving
out
of
this
who's
going
to
get
it
who's
not
going
to
get
it
who's
who
might
get
pushed
aside
as
other
communities
become
eligible
on
march
15th.
G
E
Well,
I
was
just
you
know:
it's
it's
really
challenging
as
far
as
I
can
tell
and
that
dr
pond,
I
invite
you
to
correct
me,
but
you
know
when
we
look
at
what
we
had
the
concrete
information
we
have
right.
So
we
have
what's
being
said
and
what
we
hope
is
true
with
respect
to
supply.
We
really
want
it.
We
want
it
to
come
into
the
state
desperately
we
want
to
get
people
vaccinated
desperately,
but
the
real
concrete
information
we
have
is
that
three-week
projection.
E
E
C
I
mean
I
would
echo
that
and
that
the
concrete
of
only
three
weeks
and
that
what
we
have
been
trying,
I
think
in
partnership,
you
know
with
blue
shield
and
a
sub-country.
They
have
to
really
look
at
these
projections
and
I
think
we're
really.
You
know,
I
think,
we're
all
on
the
same
page
about
that
right.
C
C
When
can
we
open
to
like
the
next
age
cohort
and
so
we're
continuing
to
try
to
do
that,
but
it
has
been
very
challenging
and-
and
the
administration
had
also
said,
the
biden
administration
that
they
would
do
that
longer
term
view,
but
I
think
it's
a
moving
target
for
them
as
well.
It's
really
exciting
news
this
week,
so
hopefully
we'll
see
more
of
the
actual
numbers
very
soon
about
you
know
what
that
partnership
with
merck
is
and
and
how
that's
going
to
increase.
But
in
the
short
term,
it's
true,
I
think
it's
really.
C
C
So
that
actually
answers
some
of
the
other
questions
in
the
chat
as
well
about
just
some
of
the
constraints
we've
seen,
but
you
know,
I
think,
we're
all
continuing
to
advocate
as
best
we
can.
A
Thank
you
we're
out
of
time
for
this
section
of
the
agenda,
and
I
know
we
have
five
more
people
who
wanted
to
comment
at
least
linnea
anthony
sylvia,
esther
and
diana.
So
I'm
hoping
we're
going
to
have
a
little
more
time
at
the
end
of
the
next
piece
of
the
agenda,
we'll
see
how
we
do
and
we'll
come
back
for
sure
to
you
all
I've
got
I've
got
it
all
recorded.
So
I
apologize
that
we
don't
have
more
time
now.
Apropos
denny's
well-stated
comment.
So
nadine
and
erica
back
to
you.
B
C
Great,
thank
you
very
much
so,
as
we've
talked
about
a
few
times
today,
super
exciting
news
about
the
johnson
johnson
emergency
use
authorization
next
slide.
Please
the
science,
our
western
state
scientific
review
group,
did
actually
meet
on
monday
night
after
the
acip.
This
advisory
committee
on
immunization
practices
had
met
on
sunday
and
monday
both
to
review
their
input
on
the
safety
and
efficacy
and
also
thinking
about
other
unique
aspects
of
this
vaccine.
C
So,
and
we
again
just
reiterate,
we're
very
lucky,
both
within
our
state
and
then
to
have
this
partnership
with
washington,
oregon
and
nevada,
to
have
a
lot
of
really
outstanding
scientific
experts,
many
of
whom
sit
on
either
this
committee
for
the
cbc
advisory
committee
or
the
fda
committee
next
slide.
Please.
C
So
I
think
you
know,
as
just
to
kind
of
talk
about
a
lot
of
the
key
points
for
this
vaccine
like
visor
and
moderna.
This
vaccine
is
safe
and
highly
effective
against
preventing
death
and
severe
covet
and
actually
hospitalization,
so
there
are
actually
no
deaths
in
the
and
the
vaccination
arm
of
this
trial
of
about
40
000
individuals.
I
got
to
listen
in
on
monday
night
to
hear
our
experts
talk
about
this
vaccine
and
I'm
really
excited
about
it
again.
C
I
know
there
are
numbers
out
there
about
the
actual
infection,
but
they're
very
different
as
far
as
comparing
the
way
they
look
at
that
data
and
the
most
important
data
about
severe
you
know
again.
Hospitalization
and
death
are
really
excellent,
like
over
90
percent
and
then
no
death.
So
technically
it
could
be
considered
100
against
death,
but
it
was
a
small
number.
The
advantages
as
we've
been
hearing
you
know
throughout
this
meeting,
or
that
this
new
vaccine
is
just
one
dose.
So
it's
a
one
and
done,
which
I
think
is
very
exciting
as
well.
C
It's
easier
to
transport
and
store
it
can
be
stored
at
standard
refrigerator
temperatures.
So
it's
another
really
important
tool
for
helping
to
end
this
pandemic.
Some
other
unique
aspects
about
this
vaccine
actually
are
that
they
actually,
unlike
some
of
the
other
trials,
they
did
some
data
collection
to
try
to
see
if
they
could
decrease
asymptomatic
or
people
with
no
symptoms
infections,
and
they
did
so.
You
know
there's
been
a
lot
of
back
and
forth
about.
Oh,
how
much
are
vaccines
decreasing
transmission.
C
Is
it
performed
very
well
against
variants?
So
that's
a
really
exciting
piece
of
news
as
well,
so
I'm
personally
very
excited
about
this.
I
think
it
is
unfortunate,
as
march
has
said
that
we,
you
know,
we
do
have
one
allocation,
that's
coming,
that's
being
ordered,
but
it's
only
about
300,
000
doses
and
then,
after
that,
our
allocation
is
looking
empty
for
the
next
two
weeks.
So
we're
you
know
trying
to
understand.
What's
going
on
with
that
and
hoping
that
there
will
be
a
flood
after
that,
but
really
gearing
up.
C
I
do
want
to
also
mention
a
lot
of
conversations
have
been
happening
both
here
at
the
state,
and
I
think
nationally
about
you
know
whether
this
vaccine
should
be
prioritized
for
certain
populations
or
not,
and
I
think
we
really
look
at
this
as
one
of
three
excellent
vaccines
and
I
think,
looking
at
different
aspects
about
storage
and
transportation
are
important
considerations
or
other
unique
aspects,
but
this
one
is
equally,
you
know
validated
in
all
populations
and
one
of
my
colleagues
dr
lou
just
mentioned.
C
You
know
the
other
great
news
as
far
as
just
logistics,
around
vaccine
districts.
Pfizer
also
recently
now
has
authorization
from
the
fda
to
be
stored
and
freezer
standard
freezer
temperature,
instead
of
ultra
low
temperature
for
up
to
two
weeks.
So
that's
also
going
to
help
just
again
getting
vaccine
into
additional
providers
that
maybe
have
been
haven't.
Had
those
resources
so
really
will
help
us,
I
hope,
get
to
some
of
our
equity
goals
as
well.
C
Let's
see,
and
did
I
mention
too-
I
think
it
does
seem
again
early
data,
but
then
maybe
there's
less
side
effects
as
well
with
the
johnson
johnson,
so
again,
really
an
outstanding
vaccine
that
we're
really
excited
to
add
to
the
mix
and-
and
then
one
last
comment
about
from
the
scientific
point
about
this
vaccine-
is
that
it
does
take
probably
about
28
days
after
the
first
dose
is
about
when
you're
protected
so
and
it's
an
important
message
in
general
about
vaccines
for
the
other
two
dose
regimens.
C
We
really
consider
protection
about
two
weeks
after
that,
second
dose.
So
the
kind
of
advantage
of
the
one
dose
is
that
you'll
be
protected
about
four
weeks
after
starting
as
opposed
to
five
or
six
weeks
after
starting
the
pfizer
and
moderna.
So
those
are
my
updates
about
johnson
and
thompson.
C
A
So
let
me
just
check
in
with
the
people
who've
got
their
hands
raised
because
I
know
you
were
left
over
from
the
last
session,
but
you
might
have
a
question
for
erica
sylvia
diana
esther
linnea
anthony
for
erica
anything
on
this
issue
and
then
we'll
go
back
to
your
questions
on
the
other
issue.
A
Okay,
anybody
have
any
questions
on
the
j
j
vaccine
for
erica.
Please
raise
your
hand.
C
One
last
comment:
I'll
make
is
I'm
looking
at
the
chat
is
just
you
know.
I
I
did
mention
again.
There's
been
a
lot
of
deliberation
about
whether
it
prioritizes
vaccine
for
certain
provisions-
and
I
think
there
are
definitely
be
logistical
considerations
that
are
going
to
be
implemented.
I
think,
with
some
of
the
concerns
and
confidence
based
on
the
the
the
numbers
that
have
been
out
there
about
efficacy.
C
We
also
really
want
to
make
sure
that
everyone
has
equal
confidence,
that
that
all
three
of
our
vaccines
are
excellent
vaccines
and
good
choices,
and
again
there
might
be
considerations
based
on
the
logistical
considerations
that
are
very
important,
but
as
far
as
safety
and
efficacy
and
ability
to
protect
people,
we
want
it
to
be
really
clear
that
all
three
of
these
vaccines
are
great.
The
best
vaccine
is
the
one
that
you
can
get,
which
is
which
you
know
lays
into
some
of
your
points
about.
C
Yes,
there
are
certainly
going
to
be
considerations
about
persons
who
logistically
it'll
be
easier
to
reach,
given
one
dose
versus
two
doses.
But
again,
you
know
really
want
to
make
sure
that
everyone
understands
and
hears
that
you
know
from
all
levels.
We
really
feel
good
about
all
three
of
these
vaccines
in
all
populations.
Thank
you.
A
D
Hi
there
russell
crawford
from
the
western
center
on
law
and
poverty
hi
everyone
I
just
wanted
to
lift
up.
I
just
spoke
on
a
panel
back
phobia
vaccine
panel
last
weekend
and
there
is
a
push
amongst
black,
a
sector
of
black
doctors,
to
really
boost
people's
confidence
in
the
j
j
vaccine
because
of
the
perception
that
maybe
it's
like
a
second-class
citizenship
vaccine
and
actually
to
show
tell
people
why
people
have
even
more
confidence
in
the
jnj
vaccine,
because
it
does
not
use
the
mrna
technology
which
is
new.
D
So
I
just
wanted
to
make
sure
that
that
was
on
our
radar
and
that
you
know
that
that
movement
is
happening
to
really
kind
of
maybe
over
correct
a
bit
for
some
of
the
lack
of
confidence
in
the
j
j
vaccine
as
kind
of
a
late,
late,
comer
or
because
it
has
you
know
a
less.
It
seems
appears
to
be
less
efficient,
effective
rather
in
terms
of
the
percentage
of.
C
Thank
you
for
lifting
that
up
and
absolutely
that
is
what
we
I
think
is
really
important,
and
we
hear
you-
and
you
know
I
just
want
to
say
one
more
time
on
that
note-
that
this
vaccine,
as
far
as
protection
from
hospitalizations
and
deaths
and
severe
infection
is,
is
as
equal
as
the
visor
and
moderna.
So
that
is
really
important
to
know.
I
think
it's
for
the
protection
that
is
most
important
about
severe
infection.
B
D
B
B
So
you
will
not
be
getting
a
second
dose
of
anything
because
it's
so
one
dose
is
a
complete
vaccination
and
I
think
that's
one
thing
that
I
I
also
wanted
to
flag,
as
we
were
just
realizing
that
you
know
we
heard
from
dr
pond
that
we,
the
state,
is
planning
to
get
we'll
be
getting
about
300
000
of
the
the
j
coming
in
and
then
we'll
be
flat
for
a
little
while.
B
But
I
also
want
to
recognize
that
300
000
doses
of
j
and
j
is
like
six
hundred
thousand
doses
of
pfizer
or
moderna
when
we're
talking
about
the
number
of
people
who
can
get
vaccinated
so
again,
just
thinking
about
what
that
you
know
what
that
means
and
how
exciting
it
is
that
we
have
a
safe,
effective,
one-dose
vaccine.
C
Yeah,
thank
you
and
I
think
just
because
I'm
seeing
it
in
the
chat
too.
Just
on
that
note.
As
far
as
there
are
discussions
about
well
two
things
anytime,
you
get
one
vaccine
series
both
with
cover
19
vaccines
and
other
vaccines.
It's
really
best
to
use
the
same
manufacturer
just
because
that's
been
studied,
so
we
really,
you
know,
really
recommend
that
people
use
the
same
manufacturer
in
series.
C
And
yes,
as
has
been
mentioned
in
the
chat,
I
think
there's
a
lot
of
discussion
and
as
we
watch
for
variants
and
do
our
detection
of
that
there's
some
discussion
about
if
there
are
vaccines
that
are
less
efficacious
and
against
certain
variants
that
probably
what
we
can,
what
the
manufacturers
can
do,
and
many
of
them
are
working
on-
is
develop
a
booster
dose,
so
that
could
be
in
the
future
a
reality
for
johnson
johnson,
in
addition
to
the
physical
so,
but
that
is
still
very
early
in
the
stages
of
need
and
and
technology
and
manufacturing.
C
But
you
know
it
could
be.
Who
knows
you
know
we
get
a
flu
vaccine
every
year
and
boosters
and
it's
a
similar
idea
to
kind
of
modify
potentially
modify
vaccine
and
get
boosters
over
time
so
more
to
come
on
that.
A
Great,
thank
you
all
for
those
comments
and
let's
go
back
to
linnea
and
then
we'll
go
to
anthony
and
then
sylvia
on
and
and
then
I
know
that
esther
and
diana
also
have
comments.
Let's
see
what
we
have
time
for
to
go
back
to
our
earlier
conversation
on
distribution,
so
lynnea,
why
don't
you
go
first,
make
sure
to
introduce
yourself.
O
Yeah
good
afternoon,
everyone
linnea
koopman's
interim
ceo,
with
the
local
health
plans
of
california.
My
predecessor,
brianna
learman,
formerly
participated
in
this
group.
So
in
part
this
is
an
introduction
and
I'm
happy
to
join
you
all.
But
mine
is
actually
a
comment
and
and
not
a
question
so,
like
others
have
already
stated,
I
think
local
plans
really
appreciate
and
applaud
the
new
equity-based
allocation
methodology
and
the
announcement
made
earlier
this
week.
I
think,
has
been
previously
discussed
in
this
group.
O
Many
of
the
individuals
living
in
those
lowest
quartile,
zip
codes
or
census
tracts
our
medi-cal
beneficiaries
and
most
of
those
are
local
plan
enrollees.
So
my
comment
is
really
on
the
outreach
to
these
these
individuals
and
and
the
strategy
and
plan
for
ensuring
they
can
access
vaccines
and
just
highlighting
what
local
plans
are
currently
doing.
Kind
of
anticipating
the
focus
on
this
population
and
then
also
anticipating
the
increase
in
supply
down
the
road.
O
A
O
As
as
the
rollout
continues
with
both
the
tpa
and
the
new
methodology,
I
think
our
our
hope
would
be
that
this
partnership
and
and
work
that's
happening
collaboratively
locally
between
the
counties
and
their
providers,
and
the
plans
can
continue
and
then
also
just
noting
that,
because
I
think
we
can
be
an
additional
resource
in
addition
to
the
cbos,
who
will
be
doing
a
lot
of
that
work
on
the
ground
as
well.
A
Thanks
lynnea
and
welcome
aboard
anthony.
N
First
of
all,
thank
you
for
the
the
efforts
on
equity
this
week.
Thank
you
for
answering
that
question
about
j
and
j,
j,
j
and
and
second
boosters.
I
do
think
that
it
would
be
helpful
for
messaging
and
maybe
providing
some
reassurance
if
there
is
a
possibility
of
a
second
booster
or
something
later
on.
You
know.
I
think
people
want
immediate
help
now,
but
if
there's,
if
they're
thinking
they're
for
closing
some
some,
you
know
something
in
the
future
or
if
there's
a
possibility
something
in
the
future.
N
I
think
that
would
help
in
the
messaging,
and
I
know
that
the
medic
all
the
medical
stuff
is
just
so
new,
but
the
more
that
there
can
be
some
clarity
to
the
public.
I
think
that
would
help
in
doing
this.
My
question
was
just
I
want
on
the
sort
of
things
I
wanted
to
just
get
clarity,
because
I
I
don't
feel
like
I
have
it
about
where
are
congregate
care
settings
in
this
in
the
prioritization.
N
Is
it
something
that
is
in
the
framework?
Is
it
not?
Is
it
something
that
counties
are
allowed
to
do
or
is
it
not?
I
I
just
don't.
I
I've
gotten
conflicting
things,
oh
and
I
would
just
love
that
there
was.
N
I
understand
that
there
was
an
issue
about
the
country
care
settings
where
there's
multiple
jurisdictions,
federal
state
like
the
immigrant
detention,
centers
and
that's
a
question,
but
I
would
I
would
just
be
curious
with
regard
to
the
other
things
and
then
the
second
question
I
had
was
just
you
know
this
week
there
was
an
issue
with
sutter
having
to
cancel
a
bunch
of
appointments,
and
I
realized
that
the
supply
issue
is
significant,
but
I'm
guessing
will
the
my
turn
system
like
fix
the
issue
that,
when,
when
those
cancellations
happen
and
they're
going
to,
if
we
are
going
to
be
in
a
continued
effort
of
scarcity,
that
there
is
so
sort
of
either
easy
risk
rescheduling
or
like
the
one-stop-shop
kind
of
way
to
to
make
sure
people
had
information.
A
Well,
I
think
maybe
we
should
start
with
erica
if
she
doesn't
mind
to
talk
about
where
congregate,
living
facilities
that
are
under
the
state's
jurisdiction
fit
in
the
prioritization
and
then
marta
would
be
great.
If
you
wouldn't
mind.
C
Yes,
I
this
is
an
ongoing
issue
that
I
think
we
are
very
close
to
addressing
and
I
do
hope
we
will
have
more
information
very
soon.
It's
a
high
priority
for
us
in
general
to
address
the
high-risk,
concrete
settings,
and
I
don't
have
an
answer
for
you
today.
A
Okay,
we
will
see
if
we
can
push
everyone
to
get
to
be
able
to
talk
about
this
in
more
detail
at
our
march
17th
meeting
we'll
keep
our
fingers
crossed
just
know
everyone
that
we
we're
pushing
and
erica's
pushing
and
everybody's
working
really
hard
to
get.
This
very
important
question
resolved
okay,
marta
on
the
sutter
supply
issue,.
E
E
So
the
inventory
numbers
that
were
in
the
system
were
much
much
much
much
much
higher
than
what
was
actually
in
their
freezer,
and
so
what
ended
up
happening
is
less
first
doses
went
to
sutter
as
a
result
of
excess
inventory.
E
When
that
happens,
they
used
second
doses
as
first
doses,
to
keep
their
appointments
so
when
they
use
second
doses,
as
first
doses,
they
didn't
have
second
doses.
That
came
with
second
doses,
for
those
second
doses
that
were
you
know,
were
used
as
first
doses,
which
just
created
a
very
difficult
cycle
for
it
and
something
that
you
can't
get
in
front
of,
and
so
what
my
turn
is
going
to
do
is
both
better
able
to
communicate
to
patients
and
get
those
appointments
rescheduled.
E
A
Okay,
thank
you,
martha
sylvia
and
then
we'll
go
to
esther.
P
Hi,
this
is
sylvia
from
disability
rights,
education
and
defense
fund.
I
I
wish
I
had
denny's
capacity
to
hold
multiple
points
and
questions
in
my
head.
P
I'm
wondering
if
some
of
that
can
also
go
towards
technical
assistance
and
help
on
getting
data,
and
I
it
may
seem
like
this
well.
Data
is
not
the
most
important
thing,
but
it's
it's
so
vital
to.
I
think
in
so
many
ways
and
we've
talked
about
this:
we've
had
the
plane
analogy
right,
we're
building
the
plane.
So,
of
course
you
build
the
most
important
parts.
The
engine,
the
wings
and
maybe
it
seems
like
data-
is
not
an
existing
thing.
P
It
wasn't
in
the
plane
before
we
haven't
collected
sexual
orientation
and
gender
identity
data
before
we
haven't
effectively
collected
disability,
functional
disability
data
before
and
it
may
just
seem
like
a
new
thing,
but
this
this
is
the
piece
that
will
continue
to
be
vital,
we'll
learn
from
that
in
all
future
pandemics
and
all
future
emergencies.
This
is
the
piece
that
will
allow
us
to
know
who,
who
are
the.
D
P
With
the
disabilities
in
our
in
the
community,
what
what's
their
race
what's
their
ethnicity,
where
do
they
live?
Where
can
they
go
for
their
their
medical
care?
Where
can
they
get
their
vaccines?
What's?
What
are
the
barriers
that
are
in
the
way?
And
I
so
I
I,
if
there's
a
way
to
just
include
that
piece
as
part
of
technical
assistance?
I
I
just
think
it's
absolutely
vital
and
wanted
to
to
raise
that.
Q
Thank
you.
My
name
is
community
based
organization
in
anthony
county.
I
do
want
to
say
that
we
had
our
first,
not
vaccination,
doses
for
farmworkers,
so
we
were
very
excited,
we're
partnered
with
the
county,
and
so
we
were
there.
We
actually
registered
over
800
farmworkers
here
the
staff.
I
just
wanted
a
more
clarity.
I
know
that
you
know,
and
everyone
who
was
an
employer
from
any
ag
sector
was,
you
know,
registered,
wanted
to
register,
and
so
I
think
that's
very
important.
Q
You
know
for
our
next
foreign
expectation
distribution.
You
know,
I
I
feel
that
you
know.
If
they're
working
in
the
you
know
in
the
office,
they
don't
have
any
contact
with.
So
I
feel
that
we
need
clarity.
I
did
see
a
lot
of
people
who
could
have
waited.
We
did
have
a
group
of
farmworkers
who
did
not
have
a
letter
or
their
check
stuff
because
they
worked
in
the
field
all
day.
Q
They
arrived
at
4
pm
and
they
were
said
no
you're
not
getting
vaccinated,
because
you
don't
have
your
letter
of
of
employment
when
you
can
see
that
they,
you
just
got
off
the
field
and
then
someone
else
drove
up
with
a
big.
You
know
suv
with
their
family
and
there
were
farmers
where
ranchers
and
the
these
are
the
letters
and
so
they
all
got
vaccinated.
Q
I
just
wanted
to
mention
that
I
think
it's
important
for
those
other
communities
that
are
going
to
be
receiving
doses,
as
as
we
continue
moving
forward
with
the
local
hospitals
and
counties.
We
do
need
more
clarity
on
that,
making
sure
that
our
essential
workers
and
those
in
the
front
lines
get
vaccinated.
A
Thank
you
esther.
It's
always
good
to
hear
exactly
what's
happening
on
the
ground
from
you
and
others
erica
anything.
You
want
to
add
to
esther's
comment.
C
I
just
want
to
kind
of
actually
even
back
to
some
of
his
comments,
just
want
to
echo
and
agree
that
you
know
I
think
one
of
the
most
challenging
so
many
things
about
this
pandemic
have
been
challenging,
but
I
think
our
data
issues
are
one
of
the
biggest
and
I
think
it's
fundamental
infrastructure
right.
C
I
mean
many
people,
even
if
they're
collecting
the
data
they're
doing
it
on
pen
and
paper,
or
so
I
think
you
know,
and
in
a
state
this
large,
with
three
million
people
and
58
counties
and
however
many
providers
we
have.
C
You
know
we
have
a
lot
of
work
to
do
to
build
up
our
infrastructure,
our
health
infrastructure
and
our
data
and
health
infrastructure,
but
absolutely
agree
with
you
that
you
know
we're
really
looking
into
investing
into
that
in
the
future
and
I
hope
collectively
we
all
kind
of
think
about
that
across
the
board-
that
we
really
need
to
have
that.
C
In
our
health
and
data
infrastructure
and
figure
out
how
to
centralize
it,
so
so
I
actually
thank
you
for
that
comment
and
and
just
want
to
acknowledge
it's
been
a
challenge,
but
really
important
and
close
to
our
hearts
and.
A
R
My
comment
is
along
the
lines
of
what
you
were
talking
about,
dr
pan
and
and
esther's
comments,
just
as
we're
now
within
phase
1b
tier
1,
where
we're
vaccinating
farm
workers,
you
know
the
ufw
foundation
has
been
helping
farm
workers
register
through
our
call
center,
but
we
immediately
flagged
the
fact
that
the
my
turn
site
only
utilizes
food
and
agriculture
and
the
aggregate
as
one
criteria,
and
so
I
just
want
to
emphasize
the
fact
that
farmworkers
should
be
its
own
criteria.
R
We
know
that
farmworkers
are
not
just
in
one
location:
they're,
moving
from
county
to
county
they're
migrant,
often
uninsured,
undocumented,
it's
a
very
vulnerable
population,
so
as
soon
as
possible.
If
we
could
separate
out
those
categories,
food
and
agriculture
is
such
a
huge
category,
which
includes
grocery
workers
and
and
others,
and
so,
if
we
truly
want
to
track
whether
we're
reaching
the
most
vulnerable,
which
we
believe
farmworkers
are
in
that
category,
then
we
really
need
to
emphasize
that
in
the
data
that's
being
collected
on
the
ground.
We
still
are.
R
You
know
those
of
us
who
are
working
with
others
on
vaccination.
Events
are
tracking
our
own
data
about
how
many
farmworkers
are
getting
vaccinated,
but
the
state
has
yet
to
be
able
to
provide
that
data.
So
I
want
to
emphasize
the
very,
very
critical
importance
of
doing
that
and
being
able
to
track
that.
So
when
we
go
back
food
and
agriculture
as
its
own
cater
category,
isn't
going
to
necessarily
mean
that
farmworkers
are
getting
vaccinated.
A
C
A
C
Oh
I'll
just
start,
and
then
I
actually,
I
think,
martin
may
be
able
to
speak
more
to
how
it's
working
with
teachers
and
I
think,
there's
a
lot
of
thought
going
in
sort
of
collected
in
partnership
on
some
of
these
issues.
And
how
do
we
develop
kind
of
ways
to
have
like
a
pop-up?
You
know
a
portal
for
a
pop-up
clinics
for
specific
populations
and
maybe
unique
codes,
but
then
working
with
navigators,
because
you
know
back
to
our
collective
points.
C
We
want
the
data,
but
we
know
some
of
the
data
and
technology
does
not
match
the
group
we're
trying
to
reach,
and
we
need
to
have
that
that
appropriate
intermediary
and
often
a
community-based
on-the-ground
trusted
partner.
So
I
think
there's
a
lot
of
work
and
over
time
we'll
continue
to
be
able
to
share
a
lot
of
that.
But
I
think
I
think
and
march
I
think
you're
more
on
top
up
to
speed
on
this
and
I
but
the
teacher
codes
and
how
that's
working,
I
think,
might
are
a
good
model.
E
E
E
The
school
districts
themselves
are
very
aware
of
who's
teaching
in
person
and
who's
teaching,
remotely
and
so
they're
able
to
to
kind
of
sort
by
occupational
risk,
and
so
by
identifying
those
who
actually
have
occupational
risk
and
quantifying
that
and
being
able
to
share
information
with
the
state,
and
so
that
we
can
give
individualized
codes
to
those
school
districts
that
actually
have
that
information,
and
then
those
can
be
distributed
to
the
individuals,
and
so
there
can
be
a
registration
process
to
get
them
vaccinated.
E
E
It's
going
to
be
a
little
bit
harder
with
communities
that
don't
have
such
an
a
defined
structure,
as
you
do
with
with
schools
to
school
districts
to
boards
of
education
and
that
we
can
communicate
in
such
an
efficient
way
that
we
can
with
teachers
but
they're
still
those
structures
do
exist,
and
so
we
we
do
envision
for
all
sorts
of
different
communities
to
be
able
to
work
with
what
we
call
group
leaders,
it's
just
the
technology
term
to
be
able
to
identify
target
populations,
release
codes,
individual
list
codes.
E
These
are
not
codes
that
get
put
up
on
twitter
and
that
everybody
can
use,
but
individualized
codes
that
are
one-time,
use
only
two
group
leaders
and
that
those
group
leaders
could
be
affiliated
with
employment.
They
could
be
affiliated.
Maybe
it's
a
regional
center
that
serves
people
with
disabilities.
It
could
be
a
community-based
organization
that
serves.
E
You
know
people
in
a
disadvantaged
community,
so
there
could
be
a
a
a
bunch
of
different
targets
that
we
could
partner
with
and
be
able
to
release
just
the
single-use
codes
that
allows
them
to
either
get
into
closed
clinics
that
are
targeted
only
for
that
population
or
to
be
able
to
kind
of
get
to
the
front
of
the
line
in
open
clinics.
So
both
of
those
are
strategies
that
we're
contemplating
to
reach
these
various
populations.
E
E
R
A
Good
good
suggestion:
okay,
we
need
to
move
on
to
our
last
agenda
topic
and
I'm
gonna
turn
the
agenda
back
to
nadine
to
introduce
our
next
speaker.
B
S
Thank
you,
dr
brooke
harrison.
Thank
you
all
for
the
opportunity
to
come
and
talk
to
you
about
the
the
the
next
part
of
the
my
turn
suite,
which
is
my
turn
volunteer,
which,
as
of
right
now,
is
now
live
at
myturnvolunteer.ca.com,
and
I'm
going
to
walk
you
through
a
little
bit
of
what
my
turn
does,
both
from
the
perspective
of
a
volunteer
director,
which
is
somebody
who's
running
a
clinic
on
the
ground
who
needs
volunteers
and
then
also
from
the
perspective
of
the
volunteer
side,
which
is
both
medical
and
general
support.
S
Volunteers.
We
are
dependent
on
my
turn
clinic,
which
means
that
basically,
if
a
clinic
is
in
my
turn
clinic
and
is
posting
opportunities
for
people
to
sign
up,
for
you
know
individual
my
turn
appointments.
They
also
can
turn
us
on
and
be
able
to
say.
We
need
x
number
of
volunteers
to
help
meet
the
needs
of
our
particular
event.
S
They
go
in
and
they
log
into
my
turn
volunteer
and
they're
able
to
create
shifts,
they're
able
to
create
these
shifts,
based
off
of
any
number
of
you
know
based
off
of
specific
times,
as
well
as
specific
roles,
so
that
they
can
then
recruit
both
medical
volunteers,
as
well
as
general
volunteers
on
the
medical
side,
there's
opportunities
for
vaccinators
vaccine
prep
or
patient
observers
on
the
general
support
side.
There's
opportunities
for
greeters,
as
well
as
volunteer
support
or
registration
support.
S
The
bottom
part
of
this
show
sort
of
volunteer
by
type,
both
in
terms
of
general
support
or
or
medical,
and
then,
if
a
particular
volunteer
director
is
assigned
to
multiple
sites,
you
can
actually
see
you
know
based
off
of
one
clinic,
how
many
people
have
signed
up
and
are
tentative
tentative,
meaning
that
either
they
haven't
completed
their
training
or
background
checks.
S
The
next
slide
shows
a
little
bit
about
what
it
looks
like
on
the
back
end
when
the
volunteer
director
sets
up
the
opportunities
and
we
have
a
full
job
aid,
as
well
as
an
opportunity
to
go
deeper
into
this
with
volunteer
directors.
But
you
can
see
on
a
snapshot.
What
does
it
look
like
over
the
course
of
a
month?
How
many
jobs
have
you
created?
How
many
of
those
opportunities
are
still
available?
S
Which
ones
have
people
signed
up,
for
it
also
gives
you
the
ability,
if
you
need
to
cancel
an
entire
shift,
you
can
do
it
in
one
place,
because
if
your
clinic
was,
you
know,
didn't
get
enough
allocation
to
run
that
day.
You
can
then
just
have
one
communication
to
your
entire
group
of
volunteers
and
allow
them
to
know
that
you
can.
You
know
they
can
come
back
to
the
system
and
rebook
the
next
slide.
So
the
next
slide
really
starts
to
talk
about
it
from
the
volunteers
perspective.
S
So
the
volunteer
director
is
certainly
the
one
who
is
asking
for
the
volunteers.
They
are
identifying
what
the
different
opportunities
are
and
they're
the
ones
managing
the
process
that
includes
you,
know
verifying
and
then
managing
those
volunteers
on
site.
From
the
perspective
of
a
medical
volunteer.
If
I'm
interested
in
being
engaged,
I
can
go
to
my
turn,
volunteer.ca
I
can
put
in
my
zip
code
and
I
can
see
what
opportunities
exist
around
where,
where
I
live
or
where
I
work.
S
S
If
I'm
a
medical
volunteer,
it
automatically
looks
up
my
medical
license
to
ensure
it's
in
good
standing
and
then,
if
I
complete
the
online
training
which
which
is
driven
by
the
the
training,
that's
required
on
the
cdph
website
and
the
cdc
website,
I'm
then
able
to
to
have
a
quick
path
towards
being
confirmed
and
then
showing
up
and
actually
completing
my
shift.
S
The
the
this
next
slide
shows
what
it
looks
like
from
a
non-medical
volunteer
or
a
general
volunteer
support,
which
is
fairly
similar.
It's
just
the
rules
are
the
roles
are
slightly
different,
and
so
you
can
be
registration
or
greeter
or
administrative
support,
and
then
you
ultimately
can
go
through
the
process.
To
then
identify
you
go
through
the
process,
finish
your
online
training,
any
other
role
requirements.
S
Some
sites
require
background
checks.
Others
have
different
stat
different
components
of
what
what
is
required
to
ultimately
show
up
on
site
and
as
long
as
that's
completed,
you
move
from
tentative
to
confirmed
and
are
able
to
actually
show
up
on
the
site.
S
I
only
have
a
couple
more
slides
here:
that'll
show
you
kind
of
the
path
through,
and
so
the
next
path
shows
what
our
homepage
looks
like
at
my
turn,
volunteer.ca.gov,
you
can
see
from
the
home
page.
You
can
fill
out
your
information
so
that
you
know
you
can
sign
up
and
we
can.
We
can
contact
you
even
if
you're
not
able
to
find
a
particular
site
today,
you'll
be
able
to
find
other
ways
to
engage
and
we'll
we'll
roll
out
as
new
clinics
roll
out
we'll
be
able
to
update
you
on
those.
S
The
next
slide
shows
what
happens
when
you
are
able
to
put
in
a
zip
code.
One
of
our
pilot
partners
is
kedran
community
health
center.
It's
actually
where
josh
friday,
our
chief
service
officer,
is
today
and
it's
where
we,
where
you're
able
to
then
say:
okay,
I'm
a
medical
volunteer.
S
I'm
I'm
happy
to
do
any
of
these
vaccinator
vaccine,
prep
or
patient.
You,
then
click
select
and
it
takes
you
to
the
next
slide.
That
shows
you.
How
you
end
can
can
select
your
individual
ships.
You
can
pick
it
based
off
of
I
can
do
an
am
or
pm,
or
that
day
I
can
do
a
full
day.
There's
a
drop
down
where
you
can
say
I
can
do
you
know
certain
days
this
week
next
week
be
able
to
identify
those
shifts
and
you
can
sign
up
for
one
or
multiple.
S
The
the
next
slide
shows
what
the
information
intake
is
which
includes
you
know.
Your
personal
is
a
little
small
on
here,
but
first
name
last
name
date
of
birth
email.
If
you're
medical,
it
asks
for
your
license,
it
does
ask
if
you've
received
your
first
or
second
second
vaccination
shots.
It
also
asks
for
the
language,
both
your
primary
as
well
as
other
languages.
You
speak
and
then
you're
also
your
ability
to
travel.
S
If
anyone
has
specific
questions
or
wants
to,
you
know
bring
a
clinic
on
board,
so
we
can
help
find
volunteers
for
you
or
if
you
are
a
volunteer
organization
that
generates
volunteers,
we
certainly
can
also
provide
you
information
to
be
able
to
share
that
with
your
membership
so
that
we
can
get
make
this
a
one-stop
shop
for
volunteers
and
those
needing
volunteers
to
help
vaccinate
all
58.
B
Thank
you
so
much
dave
that
is
fantastic.
We're
very
excited
about
my
turn,
volunteer
and
we're
running
low
on
time.
So
I'm
gonna
roll
up
a
couple
of
questions
into
one.
I
think
that
you
answered
them,
but
the
ques.
The
question
was:
can
my
turn
volunteer
work
with
private
clinics
or
tribal
clinics
or
urban
sites
can
can
any
clinic.
That's
on
my
turn.
S
So
any
clinic,
that's
in
my
turn
clinic
can
access
a
my
turn
volunteer
and
we
can
turn
that
on
if
it's
private
or
public
or
some
other
partnerships,
if
you're
in
my
turn
clinic
if
you're,
not
in
my
turn
clinic,
you
can
reach
out
to
us
and
we
can
see
what
other
support
we
can
provide.
S
But
the
whole
system
is
is
interconnected
in
the
back
end,
but
california
volunteers
does
try
to
support
in
other
ways,
including
community
outreach
and
other
ways
that
we
can
help
support
those
that
are
trying
to
support
the
vaccination
efforts.
B
And
do
volunteers
have
to
be
vaccinated
or
if
someone
signs
up
to
be
a
volunteer
specifically,
do
they
have
an
opportunity
to
get
vaccinated.
S
So
volunteers
do
not
have
to
be
vaccinated.
We
did
just
get
clarity
on
the
policy,
which
is
that
a
volunteer
that
completes
a
shift
of
four
hours
or
more
is
eligible
to
receive
a
vaccination
as
long
as
the
clinic
administrator
provides
that
approval-
and
that
is
something
that
will
be
encouraging,
we'll
be
able
to
ensure,
is-
is
known
across
the
state
so
that
people
who
are
helping
to
support
the
vaccination
effort
are
able
to
receive
their
vaccinations
as
well
after
they've
completed
a
shift.
B
Fantastic,
thank
you
so
much
dave,
that's
incredibly
exciting
and
so
we're
coming
to
towards
the
end
of
the
meeting.
I
want
to
thank
everyone
again
for
taking
your
time
for
an
excellent
meeting.
B
And
we
had
the
opportunity
today
to
do
a
a
deeper
dive
into
our
vaccine
equity
plan
into
the
of
the
third
party
administrator
in
partnership
with
govops,
to
make
sure
that
that
we
have
a
a
simple
and
straightforward
process
for
vaccine
allocation.
B
I
want
to
acknowledge
there
are
a
number
of
questions
that
folks
have
asked
in
this
meeting
and
that
folks
have
asked
you
know
several
times
in
past
meetings
that
we
are
working
to
get
information
on
the
one
thing
that
I
wanted
to
flag
or
highlight,
which
is
that
there
may
be
things
that
are
suggested
in
this
meeting.
B
For
example,
you
know
diana's
excellent
suggestion
around
pulling
out
the
farm
workers
in
terms
of
my
turn,
and
one
of
the
things
that
I
wanted
to
to
flag
for
members
of
the
cvac
is
that
there
are
times
so
with
your
many
many
many
suggestions,
and
we
take
the
pages
of
your
questions
and
suggestions
and
in
between
meetings.
We
work
with
all
of
our
departments
trying
to
track
down
answers,
and
sometimes
the
answers,
reside
between
departments
or
require
you
know
bringing
folks
together
to
do
this
work
and
oftentimes.
B
For
example,
there
may
be
a
question
that
seems
a
little
straightforward
that
we
that
the
answer
is
more
complicated,
for
example
diana.
I
was
just
thinking
about
what
you
were
saying
about.
If
we
want
to
track
data
for
farmworkers
being
vaccinated,
we
should
change
the
the
category.
In
my
turn,
it
turns
out
the
way
that
we
track
the
whether
or
not
someone
is
vaccinated
is
not
through
my
turn,
but
actually
through
care
and
that
they're
all
the
complicated
systems.
B
My
turn
tracks
the
vaccine
appointment
scheduled,
but
you
can
imagine
that
it
doesn't
validate
that
that
appointment
was
completed
and
the
question
of
whether
or
not
what
we're
trying
to
track
is
whether
the
appointment
is
completed
or
whether
the
appointment
or
scheduled
are
two
different
questions
that
require
different
teams
to
coordinate
and
understand
how
to
best
answer
the
question,
and
I
say
that
to
say
that
I
want
to
recognize
that
there
are
some
questions
that
have
been
asked
several
times.
B
You
know,
for
example,
verification
you
know
is
how
our
folks
can
can
we
give
clear
guidance
on
how
folks
should
verify,
or
you
know
whether
or
not
they're,
eligible
and
and
verification
for,
for
different
levels
of
eligibility.
For
example,
we
know
that
for
our
child
care
workers,
just
a
letter
from
your
employer
is
adequate
right,
but
for
individuals
with
with
a
pre-existing
health
conditions
right
that
question
of
how
to
do
that.
Verification.
B
To
what
extent
it's
burdensome
versus
not
requires
multiple
conversations
with
multiple
stakeholders
to
to
to
move
that
process
forward,
and
so
we
don't
always
have
an
immediate
answer
at
the
next
at
the
next
meeting.
But
I
want
to
let
folks
know
that
the
questions
that
you
are
raising,
we
are
absolutely
taking
them
back
and
it
may
take
some
time
as
we
see
with
our
announcement
on
equity.
B
We
talked
about
equity
at
our
first
meeting,
that
was
in
the
the
week
the
the
week
before
thanksgiving
right
and,
and
so,
but
I.
But
what
I
want
to
say
to
the
members
of
this
committee
is
that
the
points
that
you
raise
and
the
concerns
and
questions
that
you
lift
up.
You
know
over
and
over
and
over
again,
although
the
answers
may
not
be
simple,
our
teams
are
absolutely
taking
this
information
forward.
We're
working
very.
B
Scenes
to
be
able
to
try
to
get
answers
for
you
and
I
try
to
be,
and
and
dr
pond
and
all
of
us
who
are
parts
of
the
administration
try
to
be
as
transparent
as
possible
in
terms
of
we're
working
on
it.
We
don't
have
an
answer,
yet
the
answer
may
be
a
little
bit
more
complicated
than
we
hoped,
but
I
want
to
highlight
the
extent
to
which
this
process
and
each
of
you
as
members
of
this
body,
have
enriched
and
improved
california's
process
of
vaccine
allocation
distribution
and
implementation.
B
Your
voice
is
important.
Your
voice
is
powerful,
we're
very
grateful
for
the
diverse
chorus
of
voices
that
have
influenced
and
shaped
california's
vaccine
allocation
and
implementation
process,
and
our
commitment
to
you
is
to
continue
to
take
back
these
questions.
These
concerns
and
lift
them
up.
Try
to
do
that
difficult
work
of
waiting
through
to
try
to
find
the
answers
and
to
to
come
back
to
you
with
as
many
solutions
as
we
can.
B
It's
not
going
to
be
everything
and
I'm
sure
that
you
know
there
is
sometimes
where
folks
will
feel
disappointed
or
frustrated,
but
I
I
really
want
to
highlight
how
grateful
I
am
for
your
guidance,
your
feedback,
your
input,
particularly
as
we
heard
today-
hey
you
guys,
may
have
created
this
policy.
You
think
you
solved
the
problem,
but
the
way
that
it's
working
on
the
ground
is
not
the
way
that
we
that
I
think
that
you
intended
right.
This
is
what
we
want
to
hear
from
you.
B
This
is
the
work
that
we
want
to
do
together.
We
are
incredibly
grateful
for
your
time
and
your
partnership
and
we
look
forward
to
continuing
this
process
and
with
that
it
is
two
o'clock.
Our
next
meeting
is
march
17th
from
three
to
five
pm.
We
look
forward
to
seeing
you
then
dr
pond,
is
there
any
other
final
words
that
you
want
to
share
with
our
committee.
C
I
just
I
know
it's
time
to
show.
I
just
want
to
echo
kind
of
everything
that
you
just
said
and
just
really
again
appreciate.
The
partnership,
appreciate
that
you
are
continuing
to
ask
us
the
hard
questions
and
just
know
that
sometimes
they
are
hard
questions
and
we
are
working
hard
to
try
to
answer
them
or
resolve
them,
and
you
know,
but,
but
it's
so
crucial
that
all
of
you
do
have
this
voice
to
us
and-
and
we
really
just
thank
you
for
your
time.